<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 1998
-------------------
Watson Pharmaceuticals, Inc.
---------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-20045 95-3872914
- ------------------------------- ------------ -------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File number) Identification No.)
311 Bonnie Circle
Corona, CA 91720
- -------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (909) 270-1400
--------------
-----------------------------------------------------------
Former name or former address, if changed since last report
1
<PAGE>
Item 2. Acquisition or Disposition of Assets.
------------------------------------
On November 18, 1998, Watson Laboratories, Inc. ("Watson"), a wholly owned
subsidiary of Watson Pharmaceuticals, Inc. (the "Registrant"), completed its
acquisition from G. D. Searle & Co. ("Searle"), of the U.S. rights to three oral
contraceptive products, Tri-Norinyl(R), Norinyl(R) and Brevicon(R), for $120
million cash. The purchase price was paid from cash on hand and was determined
based on arms-length negotiation between the two parties. Watson and Searle
have also entered into a supply agreement under which Watson will have the right
to purchase these products from Searle for three years; the first two years in
finished package form and the third year in bulk tablet form.
Copies of the agreements between Watson and Searle and the Registrant's press
release dated November 18, 1998, are attached hereto as noted in Item 7., below.
Item 7. Exhibits.
---------
(c) Exhibits
10.1 Asset Purchase Agreement dated September 18, 1998 by and between Watson
Laboratories, Inc. and G. D. Searle & Co. *
10.2 Supply Agreement dated November 18, 1998 by and between Watson
Laboratories, Inc. and G. D. Searle & Co.*
99.1 Press release of Watson Pharmaceuticals, Inc. dated November 18, 1998.
(*) The Registrant has submitted a confidential treatment request relating to
certain provisions of these agreements with the Securities and Exchange
Commission.
2
<PAGE>
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: December 3, 1998 WATSON PHARMACEUTICALS, INC.
By: /s/ ROBERT FUNSTEN
Name: Robert Funsten
Title: Vice President - Legal Affairs
3
<PAGE>
WATSON PHARMACEUTICALS, INC.
EXHIBIT INDEX
FORM 8-K
Exhibit
Number Description of Document Page
- ------- ----------------------- ----
10.1 Asset Purchase Agreement dated September 18, 1998 by and between
Watson Laboratories, Inc. and G. D. Searle & Co. *
10.2 Supply Agreement dated November 18, 1998 by and between Watson
Laboratories, Inc. and G. D. Searle & Co.*
99.1 Press release of Watson Pharmaceuticals, Inc. dated November 18,
1998.
(*) The Registrant has submitted a confidential treatment request relating to
certain provisions of these agreements with the Securities and Exchange
Commission.
4
<PAGE>
EXHIBIT 10.1
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT (this "Asset Purchase Agreement") is made and
entered into September 18, 1998 (the "Effective Date") by and between G.D.
Searle & Co., a Delaware corporation and Watson Laboratories Inc., a Nevada
corporation ("Buyer").
This Asset Purchase Agreement sets forth the terms and conditions upon
which Buyer is purchasing from Seller and Seller is selling to Buyer the Assets
(as hereinafter defined).
NOW THEREFORE, in consideration of the representations, warranties,
covenants and agreements set forth herein, the parties hereto agree as follows:
1. DEFINITIONS
1.1 "Affiliate" of a party means any corporation or other business entity
controlled by, controlling or under common control with, such party. For this
purpose "control" shall mean direct or indirect beneficial ownership of more
than fifty percent (50%) of the voting or income interest in such corporation or
other business entity.
1.2 "Assets" has the meaning ascribed to such term in Section 2.
1.3 "Closing" has the meaning ascribed to such term in Section 10.1.
1.4 "Closing Date" has the meaning ascribed to such term in Section 10.1
1.5 "Confidentiality Agreement" means that certain letter agreement
between the parties dated July 24, 1997.
1.6 "DOJ" means the United States Department of Justice.
1.7 "FDA" means the United States Food and Drug Administration.
1.8 "FTC" means the United States Federal Trade Commission.
1.9 "Formulation Data" has the meaning ascribed to such term in Section
2.1.4.
1.10 "HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and the rules and regulations thereunder.
i
<PAGE>
1.11 "Intangible Assets" shall mean those assets described in Section 2.1.
1.12 "Inventory" means the inventory of the finished Products (including
samples) that is owned by Seller as of the Closing.
1.13 "Know-How" has the meaning ascribed to such term in Section 2.3.
1.14 "Law" means any federal, state, foreign, local or other law,
ordinance, rule, regulation, or governmental requirement or restriction of any
kind, and any rules, regulations, and orders promulgated thereunder.
1.15 "NDA" means a New Drug Application which is submitted to the FDA in
order to obtain approval to manufacture and/or sell a pharmaceutical product in
the United States.
1.16 "Patents" means any patent or patent application and any and all
divisions, continuations, continuations-in-part, reexaminations, reissues,
extensions, pending or granted supplementary protection, certificates,
substitutions, confirmations, registrations, revalidations, revisions, additions
and the like, of or to said patent and patent application.
1.17 "Product Materials" has the meaning ascribed to such term in Section
4.11.
1.18 "Products" means those pharmaceutical products listed on Exhibit A.
1.19 "Public Information" means information that is publicly available or
is generally known in the pharmaceutical industry.
1.20 "Registrations" has the meaning ascribed to such term in Section 2.2.
1.21 "Supply Agreement" means the supply agreement between Buyer and
Seller referred to in Section 8.3.
1.22 "Searle Labeling" means the printed labels, labeling and packaging
materials, including printed carton, container label and package inserts, as
currently used by Seller for each Product.
1.23 "Syntex Process" means, for each Product, the manufacturing process
of Seller's contract manufacturer, Syntex (F.P.) Inc. or its Affiliates, set
forth in the master batch record for each such Product, true and complete copies
of which will be delivered to Buyer as part of the technology transfer plan set
forth in Section 8.2.
1.24 "Technology Transfer" means, with respect to each Product, the
earlier of (a) Buyer's receipt of FDA approval to manufacture any Product at a
Buyer designated facility or (b) twelve (12) months after the date of the
successful manufacture of the first
ii
<PAGE>
registration batch of a Product at Buyer's manufacturing facility which meets
the release specifications for such Product.
1.25 "Territory" means the United States and its possessions.
1.26 "Trademarks" means trademark and/or service mark registrations and
applications set forth on Schedule 2.1.1
1.27 "Watson Labeling" means the printed labels, labeling and packaging
materials, including printed carton, container label and package inserts, used
by Buyer and bearing Buyer's name for each Product.
2. ASSETS BEING SOLD
Subject to the terms and conditions of this Asset Purchase Agreement, at
the Closing, Seller shall sell, transfer, assign, convey and deliver to Buyer,
its successors and assigns forever, to the extent contemplated herein, all of
the right, title, and interest of Seller in the Territory in and to the assets
listed below (collectively, the "Assets") and Buyer shall assume all rights,
title, and interest of Seller in the Territory in and to the Assets and, to the
extent contemplated herein, the Assumed Liabilities. The Assets to be sold and
rights granted hereunder are for use by Buyer only in the Territory.
2.1 Intangible Assets.
-----------------
2.1.1 Trademarks. The Trademarks identified on Schedule2.1.1.
----------
"Trademarks" also includes any copyrights and any unregistered trade dress
that are owned by Seller in the Territory which are associated solely with
the Products and (only as to trade dress) currently used on or in
association with such Products by Seller. "Trademarks" shall not include
trade dress that is primarily associated with the divisions, companies or
corporate entities of Seller or its Affiliates, nor trade dress associated
with the Products which are also associated with products not being
transferred by Seller.
2.1.2 Patents. The Patents existing as of the date hereof and as of
-------
the Closing Date, held by Seller and related to a Product, that are set
forth on Schedule 2.1.2. To the extent that any patent of Seller is used
in connection with the manufacture of a Product, but is not being
transferred hereunder, Seller shall grant Buyer a non-exclusive, perpetual,
paid-up, royalty free, irrevocable license (without right to sub-license)
to use such Patents in the Territory, with such license being restricted to
use for the Products.
iii
<PAGE>
2.1.3 Clinical Studies. All clinical and pre-clinical data
----------------
(including databases in both electronic and hard copy form) available to
Seller and its Affiliates, clinical studies completed, manuscripts for all
clinical studies, dossiers, new indications, regimens, statistical
analyses, notes, memoranda, preliminary materials and summary reports,
associated exclusively with the Products in the Territory (the "Clinical
Studies").
2.1.4. Formulation Data. Except as set forth on Schedule 2.1.4, all
----------------
discoveries, notes, memoranda, preliminary materials, inventions, dosage
forms, formulations, and other development work in the Territory (the
"Formulation Data") to the extent associated exclusively with a Product and
available to Seller and its Affiliates. Except as set forth on Schedule
2.1.4, to the extent that such Formulation Data is not exclusively
dedicated to a Product but is necessary and/or used with a Product, Seller
shall grant Buyer a non-exclusive, perpetual, paid-up, irrevocable,
royalty-free, license (without the right to sublicense) to use the
Formulation Data in the Territory with such license being restricted to use
for the Products.
2.1.5 Other Intangible Assets. Except as set forth on Schedule 2.1.5
-----------------------
and to the extent available, (i) all licenses, if any, advertising and
promotional rights, and franchise rights to the extent that such rights
relate exclusively to the Product in the Territory; and (ii) customer and
supplier lists to the extent that such lists relate to the Products in the
Territory. To the extent any other intangible assets are not exclusively
dedicated to a Product but are necessary and/or used with a Product, Seller
shall grant to Buyer a non-exclusive, perpetual, paid-up, royalty-free,
irrevocable license (without the right to sublicense) to use such other
intangible assets in the Territory with such use being restricted to the
Products.
2.2 Registrations. The regulatory files (including correspondence with
-------------
regulatory authorities) and approvals, registrations and governmental
authorizations, notes, memoranda, preliminary materials, licenses and permits,
and applications therefor, that relate to the Products in the Territory which
are set forth on Schedule 2.2 (the "Registrations").
2.3 Manufacturing Technology and Know-How. The manufacturing technology
-------------------------------------
and know-how that is exclusively used in manufacturing any Product, including
but not limited to a Syntex Process, specifications and test methods (Products,
raw material, packaging, stability and other applicable specifications),
manufacturing and packaging instructions, master formula, validation reports
(process, analytical methods and cleaning), stability data, analytical methods,
records of complaints, annual product reviews to the extent available, and other
master documents, notes, memoranda, and preliminary materials necessary to
continue manufacture, control, and release of the Products in the Territory by
Buyer (the "Know-How"); and a non-exclusive, perpetual, paid-up, irrevocable,
royalty-free, license (without the right to sublicense) to use in the
iv
<PAGE>
Territory any manufacturing technology and know-how that are necessary or used
in manufacturing any Product (but not exclusively used thereto) with such
license being restricted to use for the Products.
2.4 Safety Data Base; Adverse Drug Event. Seller shall transfer a
------------------------------------
complete copy of its safety data base in both electronic and hard copy form and
adverse drug event files (including complaints and adverse drug reports) with
respect to the Products in the Territory to Buyer; provided, however, Buyer
shall be solely responsible for and shall pay all costs associated with
converting such data base into the format from which Buyer can access that
information.
2.5 Assumed Liabilities.
-------------------
2.5.1 Assumption of Liabilities. Subject to the terms and conditions
-------------------------
of this Agreement, as of the Closing Date, Buyer shall assume, and shall be
solely and exclusively liable with respect to, and shall pay, perform, discharge
and satisfy when due, only those liabilities of Seller which are specifically
enumerated below (collectively, the "Assumed Liabilities"):
(a) all liabilities for damages to third parties or their
property arising out of the sale of the Products after the Closing Date, except
as otherwise provided in the Supply Agreement; and
(b) Buyer's other obligations under this Agreement and the
Supply Agreement.
2.5.2 No Assumption of Other Liabilities. Except for the Assumed
----------------------------------
Liabilities, Buyer is not assuming and will not in any way be liable or
responsible for any liabilities, obligations or indebtedness of Seller, whether
relating to the Assets or otherwise, of any kind or nature whatsoever, whether
due or to become due, absolute or contingent, direct or indirect, asserted or
unasserted.
3. PURCHASE PRICE
3.1 Purchase Price. Subject to the terms and conditions of this Asset
--------------
Purchase Agreement, and in consideration of the sale, conveyance, assignment,
transfer and delivery of the Assets provided for in Article 2 hereof, Buyer at
the Closing will deliver to Seller by bank wire transfer in immediately
available funds to Seller at such banking institution designated by Seller the
purchase price in the amount of one hundred twenty million United States dollars
(US $120,000,000).
3.2 Tax Allocation. The parties will cooperate in the allocation of the
--------------
purchase price for the Assets for tax purposes in accordance with Internal
Revenue Code (IRC) Section 1060 and make every effort to allocate on a
reasonable basis.
v
<PAGE>
4. REPRESENTATIONS AND WARRANTIES OF SELLER
4.1 Organization. G. D. Searle & Co. is a corporation duly organized,
------------
validly existing and in good standing under the laws of Delaware, with full
corporate power and authority to consummate the transactions contemplated
hereby.
4.2 Authority. The execution and delivery of this Asset Purchase
---------
Agreement by Seller, and the consummation and performance of the transactions
contemplated hereby, have been, or as of the Closing Date will be, duly and
validly authorized by all necessary corporate and other proceedings, and this
Asset Purchase Agreement has been, or as of the Closing Date will be, duly
authorized, executed, and delivered by Seller and, assuming the enforceability
against Buyer, subject to Section 9.2.8, constitutes the legal, valid and
binding obligation of Seller, enforceable in accordance with its terms, except
as may be limited by bankruptcy, reorganization, insolvency or other similar
laws affecting the enforcement of creditors' rights in general and subject to
general principles of equity (regardless of whether enforceability is considered
in a proceeding in equity or at law).
4.3 No Violation or Conflict. The execution and delivery of this Asset
------------------------
Purchase Agreement by Seller and the performance of this Asset Purchase
Agreement (and the transactions contemplated herein) by Seller:
(a) do not and will not conflict with, violate or constitute or result
in a default under any Law, judgment, order, decree, the articles of
incorporation or bylaws of Seller; or
(b) will not result in the creation or imposition of any lien, charge,
mortgage, claim, pledge, security interest, restriction or encumbrance of any
kind on, or liability with respect to, the Assets except as otherwise provided
herein.
4.4 Registrations. All Registrations held by Seller are listed on
-------------
Schedule 2.2. Except as set forth on Schedule 4.4, the Registrations (a) are in
the name of Seller, (b) constitute all approvals, registrations, governmental
authorizations, licenses and permits, and applications therefor which Seller has
in connection with the marketing and sale of the Products, (c) to the best
knowledge of Seller, constitute all such approvals, registrations, governmental
authorizations, licenses and permits, and applications therefor necessary for
the marketing and sale of the Products in the Territory as currently conducted
or contemplated by Seller and (d) are in full force and effect, and Seller has
no reason to believe that such Registrations will be terminated or otherwise
adversely affected due to the action of any regulatory authority.
4.5 Taxes. As of the date hereof, there are no liens for taxes upon the
-----
Assets except for liens for current taxes not yet due and payable.
vi
<PAGE>
4.6 Title to Assets. Except as set forth in Schedule 4.6, Seller has good
---------------
and marketable title to all the Assets and will convey good and marketable title
at Closing, free and clear of any and all liens, encumbrances, charges, claims,
restrictions, pledges, security interests, or impositions of any kind (including
those of secured parties). None of the Assets is leased, rented, licensed, or
otherwise not owned by Seller or its Affiliates, except as set forth in Schedule
4.6.
4.7 Absence of Certain Changes. Except as set forth in Schedule 4.7 or as
--------------------------
otherwise set forth in this Asset Purchase Agreement, since January 1, 1998, to
the best of Seller's knowledge, there has not been any material adverse change
in the Assets including, without limitation, (a) any material interference or
failure to supply the Product, or (b) to Seller's knowledge, any regulatory
issues involving the manufacture, packaging, storage or sale of the Products by
Seller or any third party manufacturer.
4.8 No Government Restrictions. Except as listed or described on Schedule
--------------------------
4.8 and except for consents the failure of which to obtain would not have a
material adverse effect, no material consent, approval, order or authorization
of, or registration, declaration or filing with, any governmental agency is
required to be obtained or made by or with respect to Seller in connection with
the execution and delivery of this Asset Purchase Agreement by Seller or the
consummation by it of the transactions contemplated hereby, except with respect
to the filing of a pre-merger notification report under the HSR Act.
4.9 Intellectual Property.
---------------------
(a) As used herein, "Intellectual Property" means with respect to the
Products: (i) Patents, (ii) all trademarks, service marks, trade dress, logos,
trade names and corporate names, and all applications, registrations, and
renewals in connection therewith, (iii) all copyrightable works, all copyrights,
and all applications, registrations, and renewals in connection therewith, (iv)
Know-How, and (v) all copies and tangible embodiments thereof.
(b) Schedule 2. 1.1 identifies each material trademark, service mark
and trade name used by Seller solely in connection with the Products, whether
registered or unregistered.
(c) Schedule 2.1.2 identifies each patent used by Seller in connection
with the Products.
(d) Except as set forth on Schedule 4.9, (i) no claim by any third
party contesting the validity, enforceability, use or ownership of any
Intellectual Property included in the Assets owned or used by Seller has been
made, is currently outstanding or, to Sellers' best knowledge, is threatened,
(ii) Seller has never received any written charge, complaint, claim, demand or
notice alleging any interference, infringement, misappropriation or violation of
any intellectual property rights of third parties nor does
vii
<PAGE>
Seller know or have any reason to know of any basis for any such charge,
complaint, claim, demand or notice, and (iii) Seller has not received any notice
that any third party has interfered with, infringed upon or misappropriated any
Intellectual Property included in the Assets.
4.10 Litigation. Except as set forth in Schedule 4.10 or for adverse drug
----------
reports, to the best of Seller's knowledge, the Assets in the Territory are not
the subject of (i) any outstanding judgment, order, writ, injunction or decree
of, or settlement agreement with, any person, corporation, business entity,
court, arbitrator or administrative or governmental authority or agency,
limiting, restricting or affecting the Assets in a way that would have a
material adverse effect, (ii) any pending or threatened claim, suit, proceeding,
charge, inquiry, investigation or action of any kind, and (iii) any court suits
filed with respect to the Products since September 1, 1996. To the best
knowledge of Seller, there are no claims, actions, suits, proceedings or
investigations pending or threatened by or against Seller in the Territory with
respect to the transactions contemplated hereby, at law or in equity or before
or by any federal, state, municipal or other governmental department,
commission, board, agency, instrumentality or authority; Seller does not know or
have any reason to know of any basis for any such claim, action, suit,
proceeding or investigation except for Public Information.
4.11 Product Materials. Except for information that is (i) prohibited to
-----------------
be disclosed by contract or Law, (ii) not reasonably available to Seller, or
(iii) of such sensitivity under customary business practices that Seller has
informed Buyer that it will not disclose such information to Buyer until
Closing, Seller has made available or delivered to Buyer, or will make available
or deliver on or before Closing (unless otherwise provided herein), copies of
all market research, advertising, promotional, marketing, and sales materials
relating, to the extent applicable, to the Products available to Seller and its
Affiliates, including but not limited to price lists (and two year historical
pricing information to the extent available), discount policies, sales terms,
special pricing and rebate arrangements and product warranty policies (the
"Product Materials"). To the best of Seller's knowledge, no other Product
Materials exist except for those materials disclosed in writing prior to or at
Closing.
4.12 No Default. Seller is not a party to, or bound by, any unexpired,
----------
undischarged or satisfied written or oral contract, agreement, indenture,
mortgage, debenture, note or other instrument under the terms of which
performance by Seller according to the terms of this Agreement will be a default
or an event of acceleration, or whereby timely performance by Seller according
to the terms of this Agreement may be prohibited, prevented or delayed, other
than as set forth in Section 8.2.
viii
<PAGE>
4.13 Compliance with Laws--FDA.
-------------------------
(i) As to each of the Products for which a NDA has been approved by the
FDA, Seller is in substantial compliance with 21 U.S.C. (S)(S)355 or 357, 21
C.F.R. Parts 314 or 430 et. seq. and all terms and conditions of the
application.
(ii) With respect to the Products, Seller is in compliance with all
applicable registration and listing requirements set forth in 21 U.S.C. (S)360
and 21 C.F.R. Part 207.
(iii) With respect to the Products, all manufacturing operations conducted
by Seller are being conducted in substantial compliance with the good
manufacturing practice regulations set forth in 21 C.F.R. Parts 210 and 211.
(iv) With respect to the Products, the Seller has not made an untrue
statement of material fact or fraudulent statement to the FDA, failed to
disclose a material fact required to be disclosed to the FDA, or committed an
act, made a statement, or failed to make a statement that could reasonably be
expected to provide a basis for the FDA to invoke its policy respecting "Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities," set forth
in 56 Fed. Reg 46191 (September 10, 1991).
(v) With respect to the Products, Seller has made or will make available
to Buyer copies of any and all reports of inspection observations, establishment
inspection reports, warning letters and any other documents received by Seller
from or issued by the FDA to Seller within the last three years that indicate or
suggest lack of compliance with the FDA regulatory requirements by Seller.
(vi) Seller has not received any written notice that the FDA has
commenced, or threatened to initiate, any action to withdraw its approval or
request the recall of any of the Products, and has no reason to believe any such
action is contemplated.
4.14 Disclosure. Except as set forth on Schedule 4.14, the
----------
representations and warranties of Seller in this Agreement, and all
representations, warranties and statements of Seller contained in any schedule,
exhibit, list or document delivered pursuant hereto, do not omit to state a
material adverse fact necessary in order to make the representations, warranties
or statements contained herein or therein not misleading. Any statement, fact
or disclosure contained in this Agreement or the schedules hereto or contained
in presentations made in writing to Buyer during the conduct of its due
diligence shall be deemed to have been disclosed for all purposes under this
Agreement and all schedules hereto.
4.15 Interim Conduct of Business. Except as disclosed in Schedule 4.15
---------------------------
and as otherwise contemplated by this Agreement, since December 31, 1997, Seller
has:
(i) not sold or agreed to sell or otherwise disposed of the
Products
ix
<PAGE>
except for sales in the usual and ordinary course of business in
accordance with Seller's past practices;
(ii) not, without limitation by the enumeration of any of the
foregoing, entered into any material transaction other than in the
usual and ordinary course of business in accordance with past
practices with respect to its business of manufacturing, selling and
distributing the Products; and
(iii) maintained good business relationships with its material
customers and suppliers, and Seller is not aware of any material
adverse event relating thereto or any material unresolved complaint
or dispute which presently exists.
Notwithstanding the foregoing, Seller shall not be deemed to have breached
the terms of this Section 4.15 by entering into this Agreement or by
consummating the transactions contemplated hereby.
4.16 Inventory. As of the Closing, Products in the Inventory shall meet
---------
the specifications therefor as set forth in the manufacturing documentation and
Registrations for such Products. The Inventory will be in good condition,
properly stored, in compliance with applicable Laws, and usable and salable in
the ordinary course of business.
5. REPRESENTATIONS AND WARRANTIES OF BUYER
5.1 Organization. Buyer is a corporation duly organized, validly existing
------------
and in good standing under the laws of the State of Nevada, with full corporate
power and authority to consummate the transactions contemplated hereby.
5.2 Authority. The execution and delivery of this Asset Purchase
---------
Agreement by Buyer, and the consummation and performance of the transactions
contemplated hereby, have been duly and validly authorized by all necessary
corporate and other proceedings, and this Asset Purchase Agreement has been duly
authorized, executed, and delivered by Buyer and, assuming the enforceability
against Seller, constitutes the legal, valid and binding obligation of Buyer,
enforceable in accordance with its terms.
5.3 No Violation or Conflict. The execution and delivery of this Asset
------------------------
Purchase Agreement by Buyer and the performance of this Asset Purchase Agreement
(and the transactions contemplated herein) by Buyer do not and will not conflict
with, violate or constitute or result in a default under any Law, judgment,
order, decree, the articles of incorporation or bylaws of Buyer, or any contract
or agreement to which Buyer is a party or by which Buyer is bound.
x
<PAGE>
5.4 No Government Restrictions. Except for consents the failure of which
--------------------------
to obtain would not have a material adverse effect, no material consent,
approval, order or authorization of, or registration, declaration or filing
with, any governmental agency is required to be obtained or made by or with
respect to Buyer in connection with the execution and delivery of this Asset
Purchase Agreement by Buyer or the consummation by it of the transactions
contemplated hereby to be consummated by it, except with respect to the filing
of a pre-merger notification report under the HSR Act.
5.5 Litigation. To the best of Buyer's knowledge, there are no claims,
----------
actions, suits, proceedings or investigations pending or threatened by or
against Buyer with respect to the transactions contemplated hereby, at law or in
equity or before or by any federal, state, municipal or other governmental
department, commission, board, agency, instrumentality or authority; Buyer does
not know or have any reason to know of any basis for any such claim, action,
suit, proceeding or investigation.
5.6 Financing. Buyer will have funds sufficient to make the payment
---------
required to by made by it under Article 3 at the time such payment is due.
6. SELLER'S COVENANTS
6.1 Conduct of Business. Seller agrees that from the date hereof until
-------------------
the Closing Date, except as specifically disclosed in Schedule 6.1 or unless
otherwise agreed to by Buyer in writing, Seller or its Affiliates will
6.1.1 except as otherwise set forth in this Asset Purchase Agreement,
maintain the Assets in good status and condition;
6.1.2 not enter into any material contract or commitment, engage in
any transaction, extend credit or incur any obligation with respect to the
Assets which is not in the usual and ordinary course of business and consistent
with Seller's normal historical business practices;
6.1.3 promptly inform Buyer of any change in the Assets that could
have a material adverse effect or of any event of which Seller becomes aware
that could have a material adverse effect on Buyer's ability to market,
manufacture or sell the Products.
6.2 Compliance with Laws. Seller shall comply in all material respects
--------------------
with all Laws and orders of any court or federal, state, local or other
governmental entity applicable to the Assets except where any non-compliance
will not have a material adverse effect.
6.3 Access. From and after the date hereof and up to Closing (except as
------
otherwise provided herein), Buyer and its authorized agents, officers, and
representatives shall have access to appropriate members of Seller's staff and
to the Assets during normal
xi
<PAGE>
business hours upon reasonable prior notice and at a time and manner mutually
agreed upon between Buyer and Seller in order to complete Buyer's due diligence
and conduct such examination and investigation of the Assets as is reasonably
necessary, provided that such examinations shall not unreasonably interfere with
Seller's operations and activities.
6.4 Post-Closing Assets. To the best of Seller's knowledge, the Assets
-------------------
described in Article 2 of this Asset Purchase Agreement and/or listed on the
pertaining Schedules, are substantially all of the assets of such categories
owned or held by Seller pertaining to the Products that should, under the
definitions set forth in Article 2, be described therein and/or listed on the
respective Schedules. If any asset owned or held by Seller is discovered after
Closing that would have been listed as an Asset on those Schedules if the
existence of such asset was known as of Closing, such asset shall be transferred
or licensed, as appropriate, to Buyer by Seller, without further payment by
Buyer, according to the principles set forth herein, i.e. assets exclusively
dedicated to a Product shall be transferred to Buyer and for assets not
exclusively dedicated to a Product, Seller shall grant Buyer a non-exclusive,
perpetual, paid-up, irrevocable, royalty-free, license (without right to
sublicense), to use such assets with such license being restricted to use for
the Products, and Seller shall have no further right to use or to license such
Assets for use with the Products.
6.5 Further Assurance. Seller shall use all reasonable efforts to
-----------------
implement the provisions of this Asset Purchase Agreement, and for such purpose
Seller, at the request of Buyer, at or after the Closing, will, without further
consideration, execute and deliver, or cause to be executed and delivered, to
Buyer such deeds, assignments, bills of sale, consents and other instruments in
addition to those required by this Asset Purchase Agreement, in form and
substance satisfactory to Buyer, as Buyer may reasonably deem necessary or
desirable to implement any provision of this Asset Purchase Agreement.
7. BUYER'S COVENANTS
7.1 Conduct of Business. Buyer agrees that from and after the date
-------------------
hereof, Buyer or its Affiliates will not engage in any transaction or take any
other action which may have the effect of inducing, providing incentives to or
encouraging Seller's customers for the Products to return Products sold by
Seller prior to the Closing Date to Seller.
7.2 Transfer of Products. Following the Closing, Buyer shall use all
--------------------
reasonable efforts and, except as otherwise set forth herein, at its own expense
to obtain as expeditiously as possible such governmental approvals and
registrations from the FDA, or similar regulatory authorities, as may be
necessary with respect to the manufacture and sale of the Products by Buyer or
its designee (other than Seller or an Affiliate of Seller).
xii
<PAGE>
7.3 Labeling. Following the Closing, Buyer shall at its own expense and
--------
as expeditiously as possible use all reasonable efforts to obtain such
governmental approvals and registrations from the FDA, or similar regulatory
authorities, as may be necessary with respect to the Watson Labeling for each
Product.
7.4 Further Assurances. Buyer shall use all reasonable efforts to
------------------
implement the provisions of this Asset Purchase Agreement, and for such purpose
Buyer, at the request of Seller, at or after the Closing, will, without further
consideration, execute and deliver, or cause to be executed and delivered, to
Seller such consents and other instruments in addition to those required by this
Asset Purchase Agreement, in form and substance satisfactory to Seller, as
Seller may reasonably deem necessary or desirable to implement any provision of
this Asset Purchase Agreement.
8. COVENANTS BY BUYER AND SELLER
8.1 Rights Retained by Seller. Seller shall retain all of the right,
-------------------------
title and interest in and to all assets and intellectual property related to the
Products outside of the Territory. Seller shall have the right to (a) reference
Registrations as described in Section 8.18, (b) have the right to manufacture
Products in the Territory as described in Section 8.4, (c) use outside of the
Territory trademarks and/or tradenames which are the same or similar to the
Trademarks (d) keep copies of the Clinical Studies, Formulation Data,
Registrations and Know-How. In addition Seller shall not be prohibited from
selling Products and products pursuant to Section 13.2.
8.2 Product Manufacturing Support.
-----------------------------
8.2.1 Syntex Know-How. The parties acknowledge that (a) the Products
---------------
were acquired by Seller from Syntex (U.S.A.) Inc. and its Affiliates ("Syntex")
in August 1995, (b) Syntex is providing manufacturing technology transfer
services to Seller for the purpose of transferring the manufacture of the
Products to Seller's facilities, (c) such services are on-going and have not yet
been completed, and (d) that Seller's obligations pursuant to Section 8.2.2 are
contingent on and subject to the fulfillment by Syntex of its obligations to
Seller. Seller cannot ensure Buyer's ability to successfully manufacture the
Products at Buyer's designated facilities. Seller shall use commercially
reasonable efforts to enforce Syntex's obligations to Seller with respect to
such manufacturing technology transfer services.
8.2.2 Technology Transfer. Buyer shall use commercially reasonable
-------------------
efforts to commence and complete the technology transfer contemplated hereunder
as soon as possible after the Closing (subject to SEARLE's timely fulfilling of
its duties hereunder). Buyer and Seller shall work together to commence
transfer of the Know-How to Buyer promptly after Closing pursuant to a
technology transfer plan to be developed by the parties as soon as practicable
following the Effective Date. Seller shall use all reasonable efforts to assist
Buyer in assuming manufacture of the Products. Buyer
xiii
<PAGE>
agrees to use the Syntex Processes and/or test methods. Seller shall have no
obligation to provide manufacturing support for any Product if Buyer elects to
use a process that is materially different from a Syntex Process. If Buyer
elects to transfer a Syntex Process, Seller shall provide reasonable access to
Seller's manufacturing facilities free-of-charge for a reasonable time period.
Thereafter, Buyer shall reimburse Seller for providing such technical assistance
at the rate of one hundred fifty dollars ($150.00) per hour, plus all reasonable
out-of-pocket expenses incurred by Seller in rendering such assistance. Seller
shall be under no obligation to provide hands-on manufacturing support for a
transferred Product following the successful manufacture of the first
registration batch of a Product at Buyer's manufacturing facility which meets
the release specifications for such Product; provided however, that
notwithstanding any other provision of this Asset Purchase Agreement, Seller
shall endeavor in good faith, to the extent that resources are available, to
provide consultation support, at the technical assistance rate shown above, to
Buyer with respect to the Products until regulatory approval for the Products
has been received. Seller shall cause its representative(s) to be available to
Buyer for technical assistance as of the date Technology Transfer efforts
commence (i.e., the delivery to Buyer of relevant Know-How documentation). For
purposes of this Section, Seller shall mean Seller or an Affiliate of Seller and
Buyer shall mean Buyer or an Affiliate of Buyer.
8.2.3 Teams. It is in the best interest of the parties to complete
-----
the technology transfer as soon as possible. To ensure that the technology
transfer is completed on time, technology transfer project teams (the
"Technology Transfer Teams") will be established as soon as practicable
following the Effective Date. The Technology Transfer Team shall consist of
sufficient representatives from each of Buyer and Seller qualified to carry out
such technology transfer activities. The first responsibility of the Technology
Transfer Teams shall be the development of the technology transfer plan referred
to in Section 8.2.2.
8.3 Supply Arrangements. Buyer and Seller, or their Affiliates, at
-------------------
Closing shall enter into the Supply Agreement, substantially in the form
attached as Exhibit B.
8.4 Patent and Know-How License. During the term of the Supply
---------------------------
Agreement, Seller shall have the non-exclusive right to use the Patents and
Know-How in the Territory to manufacture finished Products pursuant to the
Supply Agreement.
8.5 Labeling. Buyer may use the Searle Labeling on inventory of
--------
Products until such inventory is exhausted. In addition, Buyer may use the
Searle Labeling on each Product supplied by Seller or its Affiliates for Buyer
until the earlier of the date (i) the FDA or other similar and appropriate
regulatory authority approves the Watson Labeling for use on such Product and
Buyer, using all reasonable efforts, has obtained sufficient supplies of
materials with Watson Labeling for use on such Products, or (ii) twelve (12)
months following receipt of approved labeling/artwork provided, however, if at
the end of such twelve (12) month period the FDA or such other similar and
appropriate regulatory authority has not yet approved the Watson Labeling, then
such twelve (12)
xiv
<PAGE>
month period shall be extended for a period of time to be mutually agreed by the
parties (such agreement not to be unreasonably withheld) reasonably required to
obtain such approval; provided, however, that Buyer and Seller shall work
together to create interim labeling (the "Interim Labeling") that changes the
NDC number for the Products and identifies Buyer as the seller of the Products
as expeditiously as possible. The intent of the parties is that the Interim
Labeling shall be a notification filing with the FDA and the parties shall not
make any changes in the Watson Labeling that would require FDA approval with
respect to the Interim Labeling.
8.6 Use of Seller Trademarks. Buyer may use the existing stock of
------------------------
Product Material only in connection with identifying Buyer as the seller of the
Products. Other than the use of the Searle Labeling and the Product Materials
as provided herein, any use by Buyer of the trademarks, tradenames, or logos of
Seller or its Affiliates must be approved by Seller, which approval shall not be
unreasonably withheld, prior to such use.
8.7 Assignment of Trademarks. By or before Closing, Buyer and Seller
------------------------
shall prepare in good faith an assignment pursuant to which Seller agrees the
Trademarks shall be assigned to Buyer. Following Closing, Buyer shall prepare
and Seller shall execute such documents as Buyer may reasonably request in order
to record the assignment of the Trademarks. The responsibility and expense of
preparing and filing such documents and any actions required ancillary thereto,
shall be borne solely by Buyer. Notwithstanding anything contained elsewhere
herein, Buyer shall hold Seller and its Affiliates harmless from and against any
fees, penalties, fines, or third party claims due to Buyer's failure to record
any assignment of any such Trademarks pursuant to this Section, except if such
fee, penalty, fines, or third party claim is due to the conduct of Seller.
8.8 Assignment of Patents. By or before Closing, Buyer and Seller
---------------------
shall prepare in good faith an assignment pursuant to which Seller agrees the
Patent shall be assigned to Buyer. Following Closing, Buyer shall prepare and
Seller shall execute such documents as Buyer may reasonably request in order to
record the assignment of the Patents. The responsibility and expense of
preparing and filing such documents and any actions required ancillary thereto,
shall be borne solely by Buyer. Notwithstanding anything contained elsewhere
herein, Buyer shall hold Seller and its Affiliates harmless from and against any
fees, penalties, fines, or third party claims due to Buyer's failure to record
any assignment of any such Patents pursuant to this Section, except if such fee,
penalty, fines, or third party claim is due to the conduct of Seller. At
Closing, Seller will deliver to Buyer all back-up, files and other materials
relating to the prosecution of the Patents.
8.9 Assignment of Registrations. Seller and Buyer shall cooperate
---------------------------
with Buyer to ensure that the Registrations that are owned by Seller shall be
assigned to Buyer. Following Closing, Buyer shall prepare and Seller shall
execute such documents as Buyer may reasonably request in order to record the
assignment of the Registrations. The responsibility and expense of preparing
and filing such documents and any actions
xv
<PAGE>
required ancillary thereto, shall be borne solely by Buyer. In addition, Buyer
shall pay any user fees associated with any Product that accrues after Closing
but prior to transfer of such Registration. Notwithstanding anything contained
elsewhere herein, Buyer shall hold Seller and its Affiliates harmless from and
against any fees, penalties, fines, and third party claims due to Buyer's
failure to record any assignment of any such Registration pursuant to this
Section, except if such fee, penalty, fines, or third party claim is due to the
conduct of Seller.
8.10 Access to Information. Buyer and Seller will, upon reasonable
---------------------
prior notice, make available to the other, to the extent reasonably required for
the purpose of assisting Seller or Buyer in obtaining governmental approvals and
preparation of tax returns relating to the Assets, and prosecuting or defending
or preparing for the prosecution or defense of any action, suit, claim,
complaint, proceeding or investigation at any time brought by or pending against
Seller or Buyer relating to the Assets or the Supply Agreement, other than in
the case of litigation between the parties hereto, such information or records
(or copies thereof) in their possession after the Closing.
8.11 Confidential Nature of Information. The parties agree that the
----------------------------------
Confidentiality Agreement shall survive either termination of this Asset
Purchase Agreement or Closing as an independent agreement; provided, however,
that upon Closing, the restrictions on use and the confidentiality obligations
of the Confidentiality Agreement shall no longer be in effect with respect to
materials relating to the transferred Assets which Buyer obtained during its due
diligence prior to Closing.
8.12 Press Releases. Neither the Seller nor the Buyer, nor any
--------------
Affiliate thereof, will issue or cause publication of any press release or other
announcement or public communication with respect to this Asset Purchase
Agreement or the transactions contemplated hereby without the prior written
consent of the other party, which consent will not be unreasonably withheld or
delayed.
8.13 Government Filings.
------------------
8.13.1 As soon as practicable following execution of this Agreement
(but in no event later than the end of business of the day on which this
Agreement is fully executed), Buyer and Seller will cause their ultimate parent
entities to make such filings, together with a request for early termination, as
required by the HSR Act with respect to the consummation of the transactions
contemplated by this Asset Purchase Agreement. Each of Buyer and Seller will
cause their ultimate parent entities to file or cause to be filed as promptly as
practicable with the FTC and the DOJ any supplemental information that may be
requested pursuant to the HSR Act. All such filings will comply in all material
respects with the requirements of the respective laws pursuant to which they are
filed.
xvi
<PAGE>
8.13.2 Each of the parties will use its respective reasonable good
faith efforts to obtain, and to cooperate with the others in obtaining, all
authorizations, consents, orders and approvals of any governmental agencies, and
cooperate with making any filings required by the Securities and Exchange
Commission, or other similar filings, that may be or become necessary in
connection with the consummation of the transactions contemplated by this Asset
Purchase Agreement prior to or after the Closing, and to take all reasonable
actions to avoid the entry of any order or decree by any governmental agency
prohibiting the consummation of the transactions contemplated hereby; provided,
however, that "reasonable actions" shall not require any party to enter into or
agree to any litigation, administrative hearing, or agree to any divestiture.
8.14 Clinical Studies Databases. Buyer shall be solely responsible
--------------------------
for and pay all costs associated with converting any database transferred to it
pursuant to Section 2.1.3 into a format from which Buyer can access information
contained therein.
8.15 Rebates, Chargebacks, Returns.
-----------------------------
8.15.1 Rebates. Seller shall be responsible for any rebate payments
-------
with respect to the Products, whether by agreement, government mandate or
otherwise, for all Products sold prior to the Closing Date and Buyer shall be
responsible for any rebate payments with respect to the Products, whether by
agreements, government mandate or otherwise, for all Products sold on or after
the Closing Date. With respect to Products sold during the calendar quarter in
which the Closing occurs, the amount of such payments shall be prorated between
Buyer and Seller based on the number of days remaining in said quarter following
the Closing Date. If Seller or an Affiliate makes payment of rebates in its own
name due to governmental requirements (e.g. Medicaid) pertaining to Products for
which Buyer is responsible, Buyer will reimburse Seller or its Affiliate such
amount within thirty (30) days following the date Seller or its Affiliate
notifies Buyer that Seller or its Affiliate has made such payments and provides
reasonable back-up documentation thereof.
8.15.2 Contract Chargebacks. From and after the Closing Date, Buyer
--------------------
shall be responsible for all costs and expenses with respect to claims under
contract chargebacks for the Products sold after the Closing Date.
8.15.3 Floor Stock Adjustments. Seller shall be responsible for all
------------------------
claims related to floor stock adjustments with respect to Products sold by
Seller prior to the Closing Date, consistent with the First In, First Out
("FIFO") method of accounting, except with respect to any floor stock
adjustments resulting from actions taken by Buyer.
8.15.4 Returns. From and after the Closing Date, Buyer and Seller
-------
shall track lot numbers for the purposes of identifying when Products were sold;
provided, however, that Seller shall track lot numbers for each lot until six
(6) months following the expiration of such lot. Seller is responsible for
claims pertaining to all Products sold prior
xvii
<PAGE>
to the Closing Date; Buyer is responsible for claims pertaining to all Products
sold on or after the Closing Date. For those lots for which both Buyer and
Seller have sold Products, returns shall be pro-rated between Buyer and Seller
based upon the quantity of such lot sold by each party, unless otherwise agreed
by the parties, based on the count of finished goods inventory at Closing.
8.16 Exclusivity Period. If the Closing has not occurred on or
------------------
before November 1, 1998, then Seller shall have the right to solicit, accept
bids from and engage in discussions and/or negotiations with third parties for
the purchase of the Assets.
8.17 Post-Closing.
------------
8.17.1 Seller Notification No. Unless otherwise agreed by the
-----------------------
parties prior to the Closing, from the Closing Date and for a period of up to
twelve (12) weeks thereafter, Seller shall notify all customers and formularies
of the transfer of the Products to Buyer by a writing in form and substance
satisfactory to Buyer (providing Buyer with a duplicate set of mailing labels
for its use).
8.17.2 NDC Numbers. Promptly following the Closing, Buyer shall
-----------
take any and all action necessary to change the National Drug Code number for
the Products, which change shall be implemented under the Supply Agreement as
agreed upon by the parties.
8.18 Seller Right to Reference. From and after the Closing, Seller shall
-------------------------
have the right to reference the Registrations for the sole purpose of
registering, making, having made and selling products outside of the Territory.
8.19 Inventory. Seller shall sell and Buyer shall purchase all Inventory
---------
that has sufficient dating such that depletion of such Inventory, based on
historical sales trends over the previous twelve (12) months, will occur before
the expiration dating of such Inventory reaches eighteen (18) months. Such
Inventory shall be purchased at a price equal to Seller's actual Cost of
Manufacture (as such term is defined in the Supply Agreement) per cycle. At the
Closing, Seller shall deliver to Buyer a statement indicating the location and
quantity of all Inventory. As soon as practicable after the Closing, Inventory
to be purchased pursuant to this Section 8.19 shall be shipped FOB Seller's
location to a destination designated by Buyer. Buyer shall pay Seller in full
for such Inventory on the thirtieth (30th) day following Closing. All other
Inventory shall be destroyed, sold outside the Territory or made available to
Buyer pursuant to Section 3.2 of the Supply Agreement.
xviii
<PAGE>
8.20 Regulatory Matters.
-------------------
8.20.1 FDA Activity Seller and Buyer shall promptly inform the
------------
other of any activities with the FDA (including meetings, phone calls, and
correspondence, together with delivering copies of any written materials with
respect thereto) regarding the Registrations or the manufacture of Products.
8.20.2 Cooperation Buyer and Seller shall cooperate and provide
-----------
each other mutual assistance in connection with regulatory matters relating to
the Registrations or the manufacture of Products; provided, however, neither
party shall be required to assume or perform the obligations of the other party
set forth hereunder.
8.21 Best Knowledge. Whenever references are made in the representations
--------------
and warranties provisions of this Agreement to the best knowledge of either
party, such knowledge shall have been determined following reasonable and due
inquiry by such party into the subject matter relating to any such
representation and warranty.
9. CONDITIONS PRECEDENT TO CLOSING
9.1 Conditions to Obligation of Buyer. The obligation of Buyer to
---------------------------------
complete the transactions contemplated hereby is subject to the satisfaction on
or prior to the Closing Date of the following conditions (all or any of which,
except Section 9.1.9, may be waived in whole or in part by Buyer):
9.1.1 Representations and Warranties. The representations and
------------------------------
warranties made by Seller in this Asset Purchase Agreement shall have been
true and correct in all respects as of the Closing Date with the same force
and effect as though said representations and warranties had been made on
the Closing Date (except for representations and warranties made as of a
specified date, which will be true and correct in all respects as of the
specified date).
9.1.2 Performance. Seller shall have performed and complied in all
-----------
material respects with all agreements, obligations and conditions required
by this Asset Purchase Agreement to be so performed or complied with by it
prior to or at the Closing.
9.1.3 Officer's Certificate. Seller shall have delivered to Buyer a
---------------------
certificate, dated the Closing Date and executed by the Chief Executive
Officer , Chief Operating Officer or a Vice President of Seller, certifying
to the fulfillment of all conditions set forth in this Article 9.1.
xix
<PAGE>
9.1.4 HSR Act Approvals. All required waiting periods under the HSR
-----------------
Act shall have expired or been terminated or approval has been received
from the FTC or DOJ.
9.1.5 Litigation. No investigation, suit, action, or other
----------
proceeding shall be threatened or pending before any court or governmental
agency that seeks the restraint, prohibition, damages, or other relief in
connection with this Asset Purchase Agreement or the consummation of the
transactions contemplated by this Asset Purchase Agreement unless such
action would not have a material adverse effect on the Assets, taken as a
whole.
9.1.6 No Adverse Change. During the period from the date of this
-----------------
Asset Purchase Agreement to the Closing Date there shall not have occurred
or been discovered, and there shall not exist on the Closing Date except
for that which has been otherwise disclosed elsewhere in this Asset
Purchase Agreement, any condition or fact that would have a material
adverse effect on the Assets, taken as a whole.
9.1.7 Authorization. Seller shall have furnished to Buyer all
-------------
documents Buyer may reasonably request relating to the existence of Seller,
the corporate authority for and the validity of this Asset Purchase
Agreement, all in form and substance satisfactory to Buyer.
9.1.8 Proceedings and Instruments Satisfactory. All proceedings,
----------------------------------------
corporate or other, to be taken in connection with the transactions
contemplated by this Asset Purchase Agreement, and all documents incident
thereto, shall be reasonably satisfactory in form and substance to Buyer
and Buyer's counsel, and Seller shall have made available to Buyer for
examination the originals or true and correct copies of all documents which
Buyer may reasonably request in connection with the transactions
contemplated by this Asset Purchase Agreement.
9.1.9 Approval. The management and Board of Directors of Buyer shall
--------
have approved the transactions contemplated hereunder.
**
** Confidential Material Filed Separately with the Commission
xx
<PAGE>
9.2 Conditions to Obligations of Seller. The obligation of Seller to
-----------------------------------
complete the transactions contemplated hereby is subject to the satisfaction on
or prior to the Closing Date of the following conditions (all or any of which,
except Section 9.2.8, may be waived in whole or in part by Seller):
9.2.1 Representations and Warranties. The representations and
------------------------------
warranties made by Buyer in this Asset Purchase Agreement shall have been
true and correct in all respects as of the Closing Date with the same force
and effect as though said representations and warranties had been made on
the Closing Date (except for representations and warranties made as of a
specified date, which will be true and correct in all respects as of the
specified date).
9.2.2 Performance. Buyer shall have performed and complied in all
-----------
material respects with all agreements, obligations and conditions required
by this Asset Purchase Agreement to be so performed or complied with by it
prior to or at the Closing.
9.2.3 Officer's Certificate. Buyer shall have delivered to Seller a
---------------------
certificate, dated the date of the Closing and executed by the President or
a Vice President of Buyer, certifying to the fulfillment of all conditions
specified in this Article 9.2.
9.2.4 HSR Act Approvals. All required waiting periods under the HSR
-----------------
Act shall have expired or been terminated or approval has been received
from the FTC or DOJ.
9.2.5 Litigation. No investigation, suit, action, or other
----------
proceeding shall be threatened or pending before any court or governmental
agency that seeks the restraint, prohibition, damages, or other relief in
connection with this Asset Purchase Agreement or the consummation of the
transactions contemplated by this Asset Purchase Agreement unless such
action would not have a material adverse effect on the Assets, taken as a
whole.
9.2.6 Authorization. Buyer shall have furnished to Seller all
-------------
documents Seller may reasonably request relating to the existence of Buyer,
the corporate authority for and the validity of this Asset Purchase
Agreement, all in form and substance satisfactory to Seller.
9.2.7 Proceedings and Instruments Satisfactory. All proceedings,
----------------------------------------
corporate or other, to be taken in connection with the transactions
contemplated by this Asset Purchase Agreement, and all documents incident
thereto, shall be reasonably satisfactory in form and substance to Seller
and Seller's counsel, and Buyer shall have made available to Seller for
examination the originals or true and correct copies of all documents which
Seller may reasonably request in connection with
xxi
<PAGE>
the transactions contemplated by this Asset Purchase Agreement.
9.2.8 Approval. The management and Boards of Directors of Seller and
--------
Monsanto Company shall have approved the transactions contemplated
hereunder.
10. THE CLOSING
10.1 The Closing. Subject to the satisfaction of all of the conditions to
-----------
each party's obligations set forth in Article 9 hereof (or, with respect to any
condition not satisfied, the waiver in writing thereof by the party or parties
for whose benefit the condition exists), the closing of the transactions
contemplated by this Asset Purchase Agreement (the "Closing") shall take place
at 10:00 a.m. (local time) at the offices of Seller in Skokie, Illinois, or at
such other time and place as the parties hereto may agree in writing, on the
later of October 1, 1998 or the third business day following the day on which
early termination under the HSR Act has expired (the "Closing Date").
Notwithstanding the foregoing, if early termination under the HSR Act is not
granted, then the Closing shall take place on the first business day following
the expiration of all required waiting periods under the HSR Act or at such
other time agreed by the parties, but in no event later than October 19, 1998 .
The transfer of the Assets shall be deemed to have occurred as of 12:01 a.m. on
the Closing Date.
10.2 Deliveries by Seller. At the Closing, Seller shall deliver to Buyer
--------------------
in form reasonably satisfactory to Buyer, each properly executed and dated as of
the Closing Date, where appropriate:
10.2.1 Except as otherwise provided herein, such deeds, bills of
sale, endorsements, assignments, assignment agreements, and other good and
sufficient instruments of conveyance and transfer as shall be effective to vest
in Buyer free and clear title to the Assets as contemplated by this Asset
Purchase Agreement;
10.2.2 The Supply Agreement;
10.2.3 The assignment of the Trademarks as set forth in Section 8.7;
10.2.4 The assignment of the Patents as set forth in Section 8.8.
10.2.5 Except as otherwise provided herein, such agreements,
licenses, notices, and authorizations as may be necessary and sufficient to
enable the Buyer to use or operate under the Intangible Assets, Registrations,
Know-How that Buyer has requested from Seller;
xxii
<PAGE>
10.2.6 All other documents, certificates and opinions required by
Section 9.1;
10.2.7 All other previously undelivered documents, instruments or
writings required to be delivered by Seller at or prior to the Closing pursuant
to this Asset Purchase Agreement;
10.2.8 The inventory of Product Materials, copies of all written
materials relating to the Intangible Assets, and the Safety Data Base; provided,
however, that to the extent that complete copies of Product Materials, Clinical
Studies, and Formulation Data are not available at Closing, such copies shall be
delivered to Buyer as soon as reasonably possible following Closing;
**
10.2.10 Notwithstanding anything to the contrary contained herein,
representatives of Buyer and Seller (including but not limited to manufacturing,
regulatory affairs, marketing and sales personnel) shall meet following the
Effective Date to decide upon and arrange for (i) delivery and transfer of
materials and records referred to in Section 10.2.8, (ii) documents to be
delivered at Closing, including those requested by Buyer under Section 10.2.5,
and (iii) deliveries and activities following the Closing, including the
completion of documents necessary to effect and record the transfer of
Trademarks, Patents and Registrations as expeditiously as reasonably possible.
10.3 Deliveries by Buyer. At the Closing, Buyer shall deliver or cause to
-------------------
be delivered to Seller:
10.3.1 The payments set forth in Article 3;
10.3.2 The Supply Agreement;
10.3.3 All other documents, certificates and opinions required by
Section 9.2; and
10.3.4 All other previously undelivered documents, instruments or
writings required to be delivered by Buyer at or prior to the Closing pursuant
to this Asset Purchase Agreement.
** Confidential Material Filed Separately with the Commission
xxiii
<PAGE>
11. TERMINATION
11.1 Termination. This Asset Purchase Agreement and the transactions
-----------
contemplated hereby may be terminated at any time prior to the Closing Date:
11.1.1 By the mutual written consent of Seller and Buyer;
11.1.2 By either Seller or Buyer if the Closing shall not have
occurred on or before November 1, 1998, unless such date has been extended by
mutual agreement in writing;
11.1.3 By either Seller or Buyer if consummation of the transactions
contemplated hereby shall violate any non-appealable final order, decree or
judgment of any court or governmental body having competent jurisdiction.
11.1.4 By Buyer if there has been a material violation or breach by
Seller of any of the agreements, representations or warranties contained in this
Asset Purchase Agreement that has not been waived in writing, or if there has
been a material failure of satisfaction of a condition to the obligations of
Buyer that has not been waived in writing, and such violation, breach, or
failure has not been cured within sixty (60) days of written notice to Seller by
Buyer; or
11.1.5 By Seller if there has been a material violation or breach by
Buyer of any of the agreements, representations or warranties contained in this
Asset Purchase Agreement that has not been waived in writing or if there has
been a material failure of satisfaction of a material condition to the
obligations of Seller hereunder that has not been waived in writing, and such
violation, breach, or failure has not been cured within sixty (60) days of
written notice to Buyer by Seller.
11.2 Effect of Termination. If this Asset Purchase Agreement is
---------------------
terminated pursuant to Section11.1, all further obligations of Seller and Buyer
under this Asset Purchase Agreement shall terminate without further liability of
Seller or Buyer except (a) as provided in Section 16.9; and (b) that such
termination shall not constitute a waiver by any party of any claim it may have
for damages caused by reason of a breach by the other party of a representation,
warranty, covenant or agreement.
12. SURVIVAL; INDEMNIFICATION
12.1 Survival of Representations; Remedy for Breach. After the Closing,
----------------------------------------------
the sole and exclusive remedy of Buyer and Seller for any breach or inaccuracy
of any representation or warranty under this Asset Purchase Agreement by the
other party hereto shall be the indemnities contained in this Article12, which
shall survive the Closing. Any claims that a party may have arising out of the
other party's breach of its representations and warranties hereunder shall be
notified to the other party no later than eighteen (18)
xxiv
<PAGE>
months following Closing. Seller and Buyer agree to use all reasonable efforts
to mitigate any loss or damage for which they may seek indemnification under
this Article 12.
12.2 Indemnification by Seller.
-------------------------
12.2.1 Claims. Subject to the limitations set forth in
------
Section 12.2.2, Seller shall indemnify Buyer and its Affiliates
against and agrees to hold Buyer and its Affiliates harmless
from any and all damage, loss, liability, third party claims,
and expense (collectively, "Damages") (including, without
limitation, reasonable expenses of investigation and attorneys'
fees and expenses in connection with any action, suit or
proceeding brought against Buyer or its Affiliates) incurred or
suffered by Buyer or its Affiliates arising out of (a) any
misrepresentation or breach of a warranty or covenant made by
Seller herein or (b) the manufacture or sale of Products prior
to the Closing, or (c) any claims of patent infringement arising
out of Buyer's sale of Inventory following the Closing.
12.2.2 Limitations. Notwithstanding anything to the contrary
-----------
set forth elsewhere herein, Buyer and its Affiliates shall not
be entitled to indemnification hereunder with respect to any
indemnifiable claim brought under Section 12.2.1(a) unless the
amount of Damages with respect to such indemnifiable claim
exceeds seventy-five thousand dollars ($75,000). However, Seller
shall in no event be required to pay Buyer and its Affiliates
more than fifty million dollars ($50,000,000) in respect of
aggregate damages asserted pursuant to Section 12.2.1(a).
12.3 Indemnification by Buyer.
------------------------
12.3.1 Claims. Subject to the limitations set forth in Section
------
12.3.2, Buyer shall indemnify Seller and its Affiliates against and agrees to
hold Seller and its Affiliates harmless from any and all Damages (including
without limitation, reasonable expenses of investigation and attorneys' fees and
expenses in connection with any action, suit or proceeding brought against
Seller or its Affiliates) incurred or suffered by Seller or its Affiliates
arising out of (a) any misrepresentation or breach of warranty or covenant made
by Buyer herein, or, (b) the sale of Products after the Closing, except to the
extent provided otherwise under Section 8 of the Supply Agreements.
12.3.2 Limitations. Notwithstanding anything to the contrary
-----------
set forth elsewhere herein, Seller and its Affiliates shall not be entitled to
indemnification hereunder with respect to any indemnifiable claim brought under
Section 12.3.1(a) unless the amount of Damages with respect to such
indemnifiable claim exceeds seventy-five thousand dollars ($75,000). However,
Buyer shall in no event be required to pay Seller and its Affiliates more than
fifty million dollars ($50,000,000) in respect of aggregate
xxv
<PAGE>
damages asserted pursuant to Section 12.3.1(a).
12.4 Notice. A party seeking indemnification pursuant to Section 12.2 or
------
12.3 (an "Indemnified Party") shall give prompt notice to the party from whom
such indemnification is sought (the "Indemnifying Party") of the assertion of
any claim, or the commencement of any action, suit or proceeding, in respect of
which indemnity is or may be sought hereunder (whether or not the limits set
forth in Section 12.2.2 have been exceeded) and will give the Indemnifying Party
such information with respect thereto as the Indemnifying Party may reasonably
request, but no failure to give such notice shall relieve the Indemnifying Party
of any liability hereunder (except to the extent the Indemnifying Party has
suffered actual prejudice thereby).
12.5 Participation in Defense. The Indemnifying Party may, at its
------------------------
expense, participate in or assume the defense of any such action, suit or
proceeding involving a third party. In such case the Indemnified Party shall
have the right (but not the duty) to participate in the defense thereof, and to
employ counsel, at its own expense, separate from counsel employed by the
Indemnifying Party in any such action and to participate in the defense thereof.
The Indemnifying Party shall be liable for the fees and expenses of one firm as
counsel (and appropriate local counsel) employed by the Indemnified Party if the
Indemnifying Party has not assumed the defense thereof. Whether or not the
Indemnifying Party chooses to defend or prosecute any claim involving a third
party, all the parties hereto shall cooperate in the defense or prosecution
thereof and shall furnish such records, information and testimony, and attend
such conferences, discovery proceedings, hearings, trials and appeals, as may be
reasonably requested in connection therewith.
12.6 Settlements. The Indemnifying Party shall not be liable under this
-----------
Article for any settlement effected without its consent of any claim, litigation
or proceedings in respect of which indemnity may be sought hereunder, unless the
Indemnifying Party refuses to acknowledge liability for indemnification under
this Article 12 and/or declines to defend the Indemnified Party in such claim,
litigation or proceeding.
12.7 Rights of Affiliates. Any claim of any Indemnified Party under this
--------------------
Article 12 may be made and enforced by an Affiliate of such Indemnified Party.
13. NON-COMPETE
13.1 Non-Compete. In consideration of the transactions contemplated
-----------
hereunder and other valuable consideration, for the period beginning with the
Closing and ending on the seventh (7th) anniversary of the Closing, Seller and
each of its Affiliates shall not engage, except as provided in Sections 13.2 and
13.3, in the distribution or sale of any oral contraceptives which are the AB-
rated equivalents of the Products (the "Restricted Products") in the Territory.
xxvi
<PAGE>
13.2 Exception to Non-Compete. Nothing contained in Section 13.1 shall be
------------------------
construed as prohibiting Seller or any of its Affiliates from; (a) acquiring
another company, business or line of products (including by license thereof or
through investment therein), of which less than ten percent (10%) of the
revenues and/or assets represents Restricted Products and to continue to operate
such business following such acquisition; (b) entering into a joint venture,
alliance or other similar collaborative arrangement between Seller and any third
party ("Joint Venture"), of which less ten percent (10%) of the revenues and/or
assets which such third party brings to such collaboration represents Restricted
Products and to continue to participate in such collaboration, provided, the
primary purpose of any such collaboration shall not be the distribution or sale
of any oral contraceptives which are AB-rated equivalents of the Products; or
(c) continuing to develop, manufacture and sell in the Territory its other oral
contraceptive products which are not being purchased by Buyer hereunder,
provided, such other oral contraceptive products may not be AB-rated equivalents
of the Products.
**
14. NOTICES
Any notice required or permitted to be given hereunder shall be deemed
sufficient if sent by facsimile letter or overnight courier, or delivered by
hand to Seller or Buyer at the respective addresses and facsimile numbers set
forth below or at such other address and facsimile number as either party hereto
may designate. If sent by facsimile letter, notice shall be deemed given when
the transmission is completed if the sender has a confirmed transmission report.
If a confirmed transmission report does not exist, then the notice will be
deemed given when the notice is actually received by the person to whom it is
sent. If delivered by overnight courier, notice shall be deemed given when it
has been signed for. If delivered by hand, notice shall be deemed given when
received.
** Confidential Material Filed Separately with the Commission
xxvii
<PAGE>
if to Seller, to:
G.D. Searle & Co.
5200 Old Orchard Road
Skokie, Illinois 60077 USA
Attention: Chief Operating Officer
Fax number: 847-581-5005
with a copy to: Assistant General Counsel, Commercial
Fax number: (847)581-4045
if to Buyer, to:
Watson Laboratories, Inc.
P.O. Box 1900
311 Bonnie Circle
Corona, California 91718-1900
Attention: President
Fax number: (909) 270-1429
with a copy to: LEGAL DEPARTMENT
Fax number: (909) 270-1429
15. GOVERNING LAW
This Asset Purchase Agreement shall be governed by and construed in
accordance with the domestic law of the state of Illinois applicable to
agreements made and to be performed in Illinois, without regard to principles of
conflicts of laws thereof.
16. ADDITIONAL TERMS
16.1 Brokers. Buyer represents to Seller that it has not employed any
-------
investment banker, broker, finder or intermediary in connection with the
transactions contemplated hereby who might be entitled to a fee or any
commission from Seller upon consummation of the transactions contemplated
hereby. Seller represents to Buyer that it has not employed any such Person in
such connection who might be entitled to a fee or any commission from Buyer upon
consummation of the transactions contemplated hereby.
16.2 Expenses. Except as otherwise expressly provided in this Asset
--------
Purchase Agreement, all legal, accounting and other costs and expenses incurred
in connection herewith and the transactions contemplated hereby shall be paid by
the party incurring such expenses.
xxviii
<PAGE>
16.3 Assignment. This Agreement shall be binding upon and inure to the
----------
benefit of the parties and their successors and assigns. Neither Seller or
Buyer shall assign this Agreement or any rights or obligations hereunder without
the prior written consent of the other.
16.4 Entire Agreement. This Asset Purchase Agreement, the Exhibits, the
----------------
Schedules and the Confidentiality Agreement embody the entire agreement of the
parties hereto with respect to the subject matter hereof and supersede and
replace all previous negotiations, understandings, representations, writings,
and contract provisions and rights relating to the subject matter hereof.
16.5 Amendments; No Waiver. No provision of this Asset Purchase Agreement
---------------------
may be amended, revoked or waived except by a writing signed and delivered by an
authorized officer of each party. No failure or delay on the part of either
party in exercising any right hereunder will operate as a waiver of, or impair,
any such right. No single or partial exercise of any such right will preclude
any other or further exercise thereof or the exercise of any other right. No
waiver of any such right will be deemed a waiver of any other right hereunder.
16.6 Counterparts. This Asset Purchase Agreement may be executed in one
------------
or more counterparts all of which shall together constitute one and the same
instrument and shall become effective when a counterpart has been signed by
Buyer and delivered to Seller and a counterpart has been signed by Seller and
delivered to Buyer.
16.7 Severability. The parties agree that (a) the provisions of this
------------
Asset Purchase Agreement shall be severable and (b) in the event that any of the
provisions hereof are held by a court of competent jurisdiction to be invalid,
void or otherwise unenforceable, (i) such invalid, void or otherwise
unenforceable provisions shall be automatically replaced by other provisions
that are as similar as possible in terms to such invalid, void or otherwise
unenforceable provisions but are valid and enforceable and (ii) the remaining
provisions shall remain enforceable to the fullest extent permitted by law,
provided that the rights and interests of the parties hereto shall not be
materially affected.
16.8 Captions. Captions herein are inserted for convenience of reference
--------
only and shall be ignored in the construction or interpretation of this Asset
Purchase Agreement. Unless the context requires otherwise, all references
herein to Articles and Sections are to the articles and sections of this Asset
Purchase Agreement.
16.9 Survival. The provisions of Sections 8.11 (Confidential Nature of
--------
Information), 8.12 (Press Release), 15 (Governing law), 16.2 (Expenses) 16.9
(Survival) and 16.10 (No Approval) shall survive any expiration or termination
of this Agreement.
16.10 No Approval. In the event the Board of Directors of either Buyer
-----------
or Seller
xxix
<PAGE>
and/or Monsanto Company do not approve the transactions contemplated hereunder,
the other party shall have no claim or cause of action of any kind in connection
with the failure to Close due to such lack of approval.
[The remainder of this page intentionally left blank.]
xxx
<PAGE>
[This page intentionally left blank]
xxxi
<PAGE>
[This page intentionally left blank]
xxxii
<PAGE>
IN WITNESS WHEREOF, this Asset Purchase Agreement has been signed by duly
authorized representatives of each of the parties hereto as of the date first
above written.
WATSON LABORATORIES, INC. G.D. SEARLE & CO.
By /s/ ALLEN CHAO By /s/ R. DE SCHUTTER
-------------------------------- ------------------------------
Name Allen Chao, Ph.D. Name R. De Schutter
------------------------------ ----------------------------
Title: CEO Title:
---------------------------- --------------------------
Date: September 18, 1998
-----------------------------
xxxiii
<PAGE>
EXHIBIT A
PRODUCTS
--------
NORINYL 1/35 21 and 28 day
1/50 21 day
1/50 28 day
BREVICON 0.5/35 21 day
0.5/35 28 day
TRI-NORINYL 0.5/35} 21 and 28 day
1/35}
0.5/35}
xxxiv
<PAGE>
EXHIBIT 10.2
SUPPLY AGREEMENT
----------------
THIS AGREEMENT made as of this 18th day of November 1998 ("Effective
Date") by and between G.D. SEARLE & CO., a Delaware corporation ("SEARLE"), and
WATSON LABORATORIES, INC., a Nevada corporation ("BUYER").
WHEREAS, BUYER has obtained rights to certain Products (as hereinafter
defined) from SEARLE and desires to have the Products supplied by SEARLE;
NOW, THEREFORE, the parties agree as follows:
ARTICLE 1 -- DEFINITIONS
- ------------------------
1.1 "Asset Purchase Agreement" means the Asset Purchase Agreement entered into
--------------------------
between SEARLE and BUYER dated September 18, 1998.
1.2 "Batch" means one (1) production lot of a Product as listed for each
-------
Product on Schedule 1.2.
1.3 "Contract Year" shall mean each consecutive twelve (12) month period
---------------
commencing on_________, 1998 and ending on the first anniversary of such
date and each consecutive twelve (12) month period ending on an
anniversary of such date during the term hereof.
1.4 "Cost of Manufacture" has the meaning ascribed to such term in Section
---------------------
2.3.
1.5 "Initial Term" has the meaning ascribed to such term in Section 10.1.
--------------
1.6 "Packaging" means the procedures of filling, inspecting, labeling,
-----------
packaging and packing of the Products or any part thereof in accordance
with the Specifications. The terms "Package," "Packaged" and "Packaging"
in this Agreement shall have the identical meaning.
1.7 "Processing" means the compounding, component preparation, testing, and
------------
other procedures, or any part thereof, involved in manufacturing the
Products in accordance
<PAGE>
with the Specifications. The terms "Process," "Processed" and "Processing"
in this Agreement shall have the identical meaning.
1.8 "Product(s)" means the pharmaceutical products listed on Schedule 1.8,
------------
meeting the Specifications. This definition may change subject to the
provisions of Section 12.1.
1.9 "Specifications" mean the procedures, requirements, standards and other
----------------
items attached hereto as Schedule 1.9, as amended from time to time in
accordance with the provisions hereof.
1.10 "Syntex Facility" shall mean any facility used by Hoffman-LaRoche-Syntex,
-----------------
or a successor to the ownership or use of such facility, in the supply of
Products to SEARLE or its Affiliates.
1.11 Other Terms. Other defined terms used herein and not defined above shall
-----------
have the respective meanings assigned to such terms in the Asset Purchase
Agreement.
ARTICLE 2 -- PROCESSING AND PACKAGING AND PRICE
- -----------------------------------------------
2.1 Undertaking.
------------
(a) Subject to the limitations contained herein, SEARLE hereby agrees to
Process and Package or to have Processed and Packaged BUYER's orders
for the Products in the Territory and BUYER agrees to pay SEARLE for
the quantity of Products so Processed and Packaged in accordance with
this Agreement; provided, however, SEARLE shall supply Products in
(i) finished package form during the first two (2) years of the
Initial Term, and (ii) in bulk form during the third year of the
Initial Term and any extended term. Notwithstanding the foregoing,
if at any time during the first two years of the Initial Term, BUYER
obtains FDA approval to package any of the Products, BUYER at its
option, may commence ordering, subject to Section 3.3, all or any
portion of its orders for Products in bulk form, and, subject to the
limitations contained herein, SEARLE shall comply with such orders.
SEARLE shall not be obligated to Process and Package Products in
excess of the capacity limitations described in Sections 3.1 and 3.2.
(b) For the duration of this Agreement, BUYER hereby grants to SEARLE a
royalty-free, non-exclusive license and right in the Territory to use
such of the Assets as are necessary or useful to SEARLE in fulfilling
its obligations under
<PAGE>
this Agreement. (For the avoidance of doubt, under the Asset Purchase
Agreement, SEARLE retained ownership of the Assets outside of the
Territory.)
(c) The parties acknowledge that any of SEARLE's obligations hereunder
may be carried out, at SEARLE's election, by third party
manufacturers; provided that SEARLE's use of any third party
manufacturer, other than a Syntex Facility manufacturer, shall
require BUYER's prior written consent, which consent shall not be
unreasonably withheld. The use of any third party manufacturer shall
not relieve SEARLE of its obligations under this Agreement.
2.2 Price and Payment.
------------------
(a) During the Initial Term, the prices for Processing and Packaging the
Products shall be equal to the Cost of Manufacture plus **. The
prices in effect for the remainder of calendar year 1998 are set
forth in Schedule 2.2(a). Thereafter, the prices for Products may be
increased once in each calendar year by up to an amount equal to the
percent increase in the Producer Price Index for the Drugs and
Pharmaceutical Sector as reported by the Bureau of Labor Statistics
("PPI") over the prior twelve (12) months; **
(b) During any extended term following the Initial Term, the prices for
Processing and Packaging the Products shall be negotiated in good
faith by the parties.
(c) By October 31st of each calendar year of the term hereof, SEARLE
advise BUYER in writing of the prices for the following calendar
year.
(d) The Products will be shipped to a location in the Territory
designated by BUYER, FCA (Incoterms 1990) SEARLE's manufacturing
plant. Title and risk of loss shall pass to BUYER upon delivery of
the Products to the common carrier.
(e) BUYER will pay in U.S. currency for each shipment of Products within
forty-five (45) days after the date the relevant invoice is received
by BUYER or the date of shipment, whichever is later.
2.3 Definition of "Cost of Manufacture". SEARLE's cost of manufacture for the
------------------------------------
Products (the "Cost of Manufacture") (as calculated in accordance with
generally accepted accounting principles and consistent with SEARLE's
current practices) shall be equal to the sum of:
__________
** Confidential Material Filed Separately with the Commission
<PAGE>
(a) Costs of any third party manufacturers, utilities, materials,
indirect materials and supplies used in the Processing and Packaging
of Products;
(b) Wages of those employees directly employed in the Processing and
Packaging of the Products (or an appropriate portion of such wages
and salaries if such personnel are not employed exclusively in said
manufacture);
(c) Wages of employees directly employed in quality control, materials
management or related functions which are applicable to the
Processing and Packaging of Products and the salaries of the
supervisors of said functions (or an appropriate portion of such
wages and salaries if such personnel are not employed exclusively in
said manufacture);
(d) That portion of payroll taxes, benefits, social security payments,
vacation and bonus payments and other employee costs allocable to the
wages and salaries (except for severance, relocation, transfer or
other extraordinary items) included within the provisions of
subparagraphs (b) and (c) above; and
(e) That portion of SEARLE's manufacturing overhead expenses, based on
the manufacturing facility operating at full capacity during normal
business hours (one 8-hour shift), apportioned, in accordance with
generally accepted accounting principles and SEARLE's current
practices, to the manufacture of the Products supplied to BUYER.
2.4 Records of SEARLE. SEARLE shall keep records of its Cost of Manufacture
------------------
in accordance with generally accepted accounting principles in the United
States. Such records shall be maintained by SEARLE for a period of two
(2) years.
2.5 Audit. Not more frequently than once each year, BUYER at its expense
------
through an independent auditor of its choice to whom SEARLE has no
reasonable objection and subject to the provisions of Section 2.7, shall
have the right to conduct an examination or audit of said records of
SEARLE in order to verify that amounts paid to SEARLE hereunder are
correct. SEARLE agrees to cooperate fully with the auditor and to provide
all reasonable access to records and employees necessary to promptly
complete this audit. To the extent Products are purchased by SEARLE from
a third party manufacturer under a "cost" or "cost plus" arrangement and
SEARLE has the right to audit such costs, then BUYER, at BUYER's expense
and reimbursement of any costs to SEARLE, may elect to have SEARLE conduct
an audit of such costs pursuant to such
<PAGE>
rights and conditions as SEARLE may have with respect to audits of such
third party manufacturer. Subject to such rights and conditions, SEARLE
shall promptly disclose the results of such audit to BUYER.
2.6 Adjustments. In the event any examination or audit of the records of
------------
SEARLE discloses an under- or overpayment hereunder, written notice of
such fact, specifying the amount and basis of the under- or overpayment
shall promptly be furnished to both parties by the person(s) performing
the examination or audit. In the event of an overpayment the amount
thereof shall be credited against future amounts owed to SEARLE hereunder,
or if there will be no such future amounts, SEARLE shall refund the
overpayment to BUYER within thirty (30) days of such notice. In the event
of an underpayment, BUYER shall pay the amount thereof to SEARLE within
thirty (30) days after such disclosure.
2.7 Scope of Examination and Audit. The examination and audit provided for in
-------------------------------
Section 2.5 shall be restricted to those records of SEARLE which relate to
the services provided hereunder and costs and expenses incurred hereunder,
and shall be undertaken for the sole purpose of verifying information
provided by SEARLE and payments made to SEARLE hereunder. The independent
auditor shall not disclose to BUYER any information obtained in the course
of its audit other than information relating solely to the accuracy of the
statements provided by SEARLE and payments to be made to SEARLE pursuant
to this Agreement. BUYER, its representatives and any independent auditor
appointed by it shall keep all information obtained in the course of any
examination or audit confidential, except to the extent disclosure of
under- or overpayment is contemplated herein. If the auditor determines
that SEARLE has overcharged the BUYER by five per cent (5%) or more for
the Products purchased by the BUYER for the period audited, SEARLE agrees
to promptly reimburse the BUYER for all costs and expenses incurred by
BUYER in having said audit conducted.
ARTICLE 3 -- FORECASTS AND ORDERS
- ---------------------------------
3.1 Forecasts.
----------
(a) At least thirty (30) days prior to each calendar quarter, BUYER will
provide SEARLE with a written twelve (12) month rolling forecast of
the quantities of
<PAGE>
each Product that BUYER expects to purchase during each of the next
twelve (12) months (the Twelve Month Forecast"); provided, however,
the first Twelve Month Forecast shall be attached hereto as Schedule
3.1(a)-I. Except as may be provided otherwise in this Section 3, the
forecast for each Contract Year will be limited to an amount not
greater than one-hundred thirty percent (130%) of the forecast for
the prior Contract Year. For purposes of bench-marking the current
forecast for the prior Contract Year to which BUYER will be limited
under this Section 3.1(a), attached as Schedule 3.1(a)-II is the most
recent Contract Year forecast.
(b) The first three (3) months of each Twelve Month Forecast (the "Three
Month Forecast") shall be firm and shall not have been changed from
the forecasted amounts for the same calendar months contained in the
prior Twelve Month Forecast.
3.2 Permitted Amount To be Ordered. BUYER shall submit a purchase order to
-------------------------------
SEARLE referencing this Agreement each month as required, with a delivery
date of not less than ninety (90) days after the date thereof. The
quantities ordered will be no less than eighty percent (80%) of the Three
Month Forecast for such month and no more than the greater of one hundred
twenty percent (120%) of the Three Month Forecast for such month or an
additional Batch, provided raw materials are available for the amounts
over one hundred percent (100%) of the Three Month Forecast. SEARLE will
use its reasonable efforts, but will be under no obligation, to supply
Product in excess of one hundred twenty percent (120%) of the Three Month
Forecast. Products, when delivered to the common carrier under subsection
2.2(d), shall not have an expiration date of less than twenty-four (24)
months(for both finished and bulk Products) from the date of such
delivery, except (a) for the bridging inventory described under Section
------
3.4, and/or (b) as the parties may agree otherwise in writing on a case by
case basis. With respect to subsection (b), SEARLE shall notify BUYER in
writing when and if it has Products which have an expiration date of less
than twenty-four (24) months (but in no event less than eighteen (18)
months) and BUYER shall notify SEARLE within three (3) days of receipt of
such notice whether it wishes to accept such Products. In the event BUYER
accepts such short-dated Products and BUYER's customer(s) later return
such Products solely as a
<PAGE>
result of their being short-dated, then SEARLE shall reimburse BUYER for
the actual amount refunded or credited to BUYER's customer(s) for such
returned Products and the reasonable expenses related to processing such
returned Products. The record-keeping and audit provisions of Sections
2.4, 2.5, 2.6 and 2.7 shall apply mutatis mutandis to SEARLE's right to
audit BUYER's Product returns records pursuant to Section 2.2.
3.3 Minimum Order Size. The minimum size of any order for any Product shall
-------------------
be one Batch of such Product with larger orders being in whole number
multiples of a Batch. Subject to Section 3.2, there is no minimum order
size for any Product in finished package form. To the extent BUYER's
orders for the Product Norinyl 1/50 are less than the Batch lot size for
such Product stated on Schedule 1.2, BUYER shall purchase at Searle's Cost
of Manufacture any bulk tablets that SEARLE was required to manufacture or
purchase in order to meet BUYER's orders for the Product Norinyl 1/50 to
the extent such bulk tablets may not be processed into finished goods with
acceptable dating hereunder; provided, however, that BUYER shall purchase
all such bulk tablets (regardless of expiration dating) upon the
commencement of the third year of the Initial Term or, if earlier, at such
time as BUYER commences ordering Products in bulk form.
3.4 Bridge Inventory. Prior to the expiration of the Initial Term or extended
----------------
term, as the case may be, if so requested by BUYER, SEARLE shall use
reasonable efforts to assist BUYER in obtaining a stock pile of inventory
of the applicable Products to the extent such stock pile is necessary in
order to bridge the period beginning with such expiration and the
commencement of BUYER's manufacture thereof. BUYER shall be responsible
for providing sufficient notice to SEARLE of the amount of inventory so
required by BUYER within the usual capacity limitations of SEARLE's
facility and/or a Syntex Facility.
3.5 Allocation of Product. In the event SEARLE is unable to meet both BUYER's
---------------------
orders for Products hereunder and SEARLE's or its Affiliates' requirements
of oral contraceptive products (containing Active Ingredients) outside of
the Territory due to a shortage of Active Ingredients, then SEARLE shall
allocate Active Ingredients available to it to the Processing of Products
hereunder in an amount equal to the percent which BUYER's purchases of
Products in the preceding six (6) months bears to the total
<PAGE>
amount of (a) Products purchased by BUYER, and (b) oral contraceptive
products (containing Active Ingredients) supplied to SEARLE or its
Affiliates in the preceding six (6) months.
3.6 Safety Stock. During the term of this Agreement SEARLE shall maintain, at
------------
its expense and at a location mutually agreed by the parties, a safety
supply of inventory of each Product in bulk form (the "Safety Stock"). As
soon as reasonably practicable after the execution of this Agreement,
SEARLE shall commence building the Safety Stock. The size of the Safety
Stock shall be an amount equal to three (3) months inventory of each
Product based on BUYER's most recent Twelve Month Forecast (for Products
other than any Bridge Stock).
3.7 Failure to Supply.
------------------
(a) In the event SEARLE fails or is unable to supply the quantities of
the Products ordered by BUYER to meet BUYER's requirements (within
the limits described in Section 2.1 above), BUYER may (i) purchase or
obtain so much as to meet its requirements or any portion thereof
from any other source or (ii) to the extent permitted by law
manufacture the same under the applicable Specifications and quality
control procedures. In such event, SEARLE shall provide BUYER or
BUYER's contract manufacturer with all documents, data and other
information necessary or useful for Processing and Packaging the
Products at no cost for so long as SEARLE is unable to supply
sufficient quantities of the Products to meet BUYER's requirements.
**
ARTICLE 4 -- SPECIFICATIONS
- ---------------------------
4.1 Specifications. The Products shall be Processed, Packaged, stored and
--------------
shipped in accordance with the Specifications.
4.2 BUYER'S Changes. The Specifications may be changed by BUYER, provided the
---------------
Specifications at all times shall be in compliance with the Product
Registration, from time to time with SEARLE's consent which shall not be
unreasonably withheld, but not more often than twice per year unless
required by the FDA or other U.S. government agency. All such changes
shall be communicated to SEARLE in writing, after which the parties shall
agree on the date of implementation of such changes as soon as reasonably
__________
** Confidential Material Filed Seperately with the Commission
<PAGE>
practicable. If any such change results in obsolescence of any materials
specifically purchased by SEARLE for Processing and Packaging of the
Products under this Agreement prior to being notified in writing by BUYER
of the change in the Specifications, BUYER shall reimburse SEARLE for the
actual out-of-pocket cost of all such materials except to the extent the
quantity of such materials exceeds requirements therefor pursuant to
BUYER's forecasts. Upon being reimbursed and at BUYER's request, SEARLE
shall promptly ship any such materials to a location designated by BUYER at
BUYER's expense. If any such change or proposed change to the
Specifications results in costs and expenses to SEARLE, BUYER shall
promptly reimburse all such reasonable costs and expenses to the extent
that such costs and expenses are not included in SEARLE's revised Cost of
Manufacture and recovered within twelve (12) months of implementation of
the change.
4.3 SEARLE Changes. SEARLE may change the Specifications at any time upon
--------------
sixty (60) days prior written notice to BUYER, provided the Specifications
at all times shall be in compliance with the Product Registrations. Any
changes to Specifications under this Section 4.3 shall be subject to
BUYER's reasonable objections thereto, provided that any objections to such
changes shall be delivered in writing to SEARLE within fifteen (15) days of
BUYER's receipt of notice of such changes.
ARTICLE 5 -- RAW MATERIALS AND PACKAGING MATERIALS
- --------------------------------------------------
5.1 Supply. SEARLE will supply all materials required for Processing and
------
Packaging.
5.2 Title and Risk of Loss. Title and risk of loss to all materials provided
-----------------------
by SEARLE shall pass to BUYER upon delivery of the finished Products
incorporating such materials to the common carrier at SEARLE's
manufacturing plant. SEARLE shall store and maintain all raw and packaging
materials in accordance with the Specifications and in compliance with all
applicable laws and regulations.
ARTICLE 6 -- QUALITY CONTROL; ADVERSE EXPERIENCES AND RECALLS
- -------------------------------------------------------------
6.1 Testing. SEARLE shall perform quality control tests and assays on raw
--------
materials and the finished Products in accordance with the Specifications
and GMPs (as defined in Section 7.1(a)). Results of such tests and assays
as well as specific batch samples of Products manufactured under this
Agreement following the date hereof will be submitted to
<PAGE>
BUYER for the first Batch of each Product during any Contract Year and each
fifth (5th) Batch in such Contract Year thereafter. In the event of any
such request, BUYER will review the data and samples submitted by SEARLE
promptly and will advise SEARLE of its acceptance or rejection of each lot
or batch of the Products not later than thirty (30) days after the date on
which results of the tests and assays and samples are received.
6.2 Samples. SEARLE shall retain for at least one (1) year after the
--------
expiration date of the applicable lot or batch of Products a file sample
properly stored from each lot or batch of Products Processed or Packaged,
including market packages, sufficient to perform each quality control test
specified in the Specifications at least two (2) times.
6.3 Adverse Drug Experiences and Quality Complaints. SEARLE shall be
------------------------------------------------
responsible for handling all Product complaints (including product quality
complaints and adverse drug experience reports) during the first six (6)
months following the date hereunder. To the extent requested by BUYER,
SEARLE will provide reasonable assistance in providing data available to
SEARLE relating to the Products for BUYER's regulatory annual reports
required with respect to such six months period. Thereafter, BUYER shall
be responsible for handling all such Product complaints related to all
Products. SEARLE and BUYER shall promptly forward any Product complaints
received by either of them to the other no later than three (3) days
following receipt and shall provide assistance in investigating such
complaints as may be reasonably requested. Each party shall designate a
representative who will handle Product complaints activities for such party
and coordinate such activities with the other party. However, BUYER's
handling of complaints shall in no way waive, modify or diminish any of
SEARLE's obligations under this Agreement except as otherwise provided in
Article 8 hereof.
6.4 Recalls. Recalls of the Products from the market shall be the
--------
responsibility of BUYER and may only be initiated by BUYER. BUYER may
initiate a recall by notifying SEARLE and, immediately thereafter, both
parties shall discuss appropriate alternatives, including whether a recall
is required and the method of implementing a recall. SEARLE shall
cooperate with BUYER in the event of any recall, field alert or similar
event and provide such assistance in connection therewith as BUYER may
reasonably request. The costs of any such recall shall be borne (a) by the
party whose negligence, breach of this Agreement or other conduct resulted
in such recall, or (b) equally by the parties if neither
<PAGE>
party's negligence, breach of this Agreement or other conduct resulted in
such recall.
ARTICLE 7 -- WARRANTIES
- -----------------------
7.1 SEARLE Warranties. SEARLE warrants that:
------------------
(a) the Processing and Packaging and all materials furnished by SEARLE or
any third party manufacturer pursuant to subsection 2.1(c) will
comply with the Specifications and with all applicable laws, rules,
orders and regulations, including all current Good Manufacturing
Practices ("GMPs") and will not infringe any currently existing United
States patents held by any person or entity;
(b) the Products, when delivered to the common carrier under subsection
2.2(d), shall neither be adulterated nor misbranded within the meaning
of the United States Food, Drug and Cosmetic Act, 21 U.S.C. (S)(S)301c
et. seq.; and
(c) EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, SEARLE
MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OR
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
7.2 BUYER Warranties. BUYER warrants that:
-----------------
(a) to the extent that it provides any materials or engages in Processing
or Packaging with respect to the Products, all such materials,
Processing and Packaging will comply with the Specifications and with
all applicable laws, rules, orders and regulations, including GMPs;
and
(b) subject to SEARLE's compliance with the warranties stated in Section
7.1 above, the Products which BUYER distributes and sells will not be
adulterated or misbranded within the meaning of the United States
Food, Drug and Cosmetic Act, 21 U.S.C. (S)(S)301c et. seq.
7.3 Inspection.
-----------
(a) SEARLE agrees to permit BUYER's designated representatives to whom
SEARLE has no reasonable objection to inspect SEARLE facilities at
which the Products are Processed, Packaged, stored or tested for the
purpose of
<PAGE>
determining compliance with applicable regulations and the
Specifications at reasonable times after reasonable notice during
regular business hours.
(b) SEARLE will conduct routine quality assurance audits of its third
party manufacturer's facility at which Products are Processed,
Packaged, Stored or tested at least once in each calendar year.
Subject to the terms of SEARLE's supply contract with such third party
manufacturer, BUYER shall have the right to (i) accompany SEARLE on
its inspections of such third parties' facilities at which the
Products are Processed, Packaged, Stored or tested, and (ii) receive
copies of information obtained by SEARLE from such third party
relating to the quality, safety and regulatory status of the Products.
SEARLE shall make commercially reasonable efforts to obtain the
consent of such manufacturer to the activities contained in items (i)
and (ii).
(c) BUYER's exercise of these rights shall in no way waive, modify or
diminish SEARLE's obligations under this Agreement.
7.4 Quality Control Evaluation. Within thirty (30) days after receipt of each
---------------------------
shipment, BUYER will inspect and make a quality control evaluation of such
shipment (which shall include a certificate of analysis). In the event any
shipment or part thereof fails, or there is manifest cause for BUYER to
reasonably believe that any shipment or part thereof fails, to conform to
the Specifications or shall have been Processed, Packaged or shipped under
conditions which do not comply with the FDA requirements or the provisions
of this Agreement, BUYER may reject the same by giving prompt written
notice to SEARLE specifying the manner in which it fails to meet the
requirements hereof. SEARLE shall have thirty (30) days within which to
accept or reject BUYER's claims. BUYER may withhold payment for any
shipment of Products that fails to meet the requirements hereof.
7.5 Disputes. In the event of any dispute as to whether any shipment of
---------
Products fails in whole or part to meet the Specifications, such dispute
shall be promptly resolved by an independent testing organization of
recognized repute within the U.S. pharmaceutical industry mutually agreed
upon by the parties, the appointment of which shall not be unreasonably
withheld by either party. Until any dispute is resolved, BUYER will not
dispose of any nonconforming shipment without prior written authorization
from and agreement with SEARLE. The fees and costs of such testing
organization shall be
<PAGE>
borne by the party whose position is not sustained by the testing
organization.
7.6 Replacement Products. If any Products shipped hereunder are properly
---------------------
rejected by BUYER, SEARLE agrees to ship as soon as reasonably possible
after notice of such rejection (or if there is a dispute with regard to
the rejection, after notice of the determination of the independent
testing organization) replacement Products either newly manufactured or,
with the consent of BUYER, reworked from the rejected shipment using an
FDA approved procedure with respect thereto. BUYER's exclusive remedy for
SEARLE's breach of Section 7.1, shall be to receive replacement or
reworked Product as provided herein.
7.7 Government Inspections/Communications. Each party shall promptly notify
--------------------------------------
the other party of any government inspections or communications to or from
any governmental agency (including the reporting of adverse drug
experiences or field alerts) which might (i) adversely affect SEARLE's
ability to perform its obligations under this Agreement or (ii) result in
an inspection of the facilities at which SEARLE, or its third party
manufacturer (upon receipt of notice thereof by SEARLE from such third
party manufacturer), manufactures the Products. Communications or
inspectional findings resulting from such government inspections or
communications relating to Product Registrations received by either party
will be communicated to the other party and, if practicable, such party
shall provide the other party with a reasonable opportunity to provide
input in any response, investigation, or inspection.
ARTICLE 8 -- INDEMNIFICATION
- ----------------------------
8.1 In Favor of SEARLE. BUYER shall defend, indemnify and hold SEARLE, its
-------------------
Affiliates and the officers, directors and employees of each harmless from
and against any and all claims, demands, losses, damages, liabilities,
settlement amounts, costs or expenses whatsoever (including reasonable
attorneys' fees) arising from or related to any claim, action or
proceeding made or brought against such party by a third party (i) as a
result of BUYER's use, promotion, sale and/or distribution of the Products
unless such liability arises from SEARLE's breach of any warranty or
representation herein, SEARLE's failure to perform any covenant herein, or
the negligent act or omission of SEARLE in performing its obligations
under this Agreement or (ii) arising from the failure of BUYER to conduct
a recall of any of the Products requested by SEARLE.
<PAGE>
8.2 In Favor of BUYER. SEARLE shall defend, indemnify and hold BUYER and its
------------------
officers, directors and employees harmless from and against any and all
claims, demands, losses, damages, liabilities, settlement amounts, costs
or expenses whatsoever (including reasonable attorneys' fees) arising from
or related to any claim, action or proceeding made or brought against such
party by a third party as a result of (i) SEARLE's breach of any warranty
or representation herein, SEARLE's failure to perform any covenant herein,
or the negligent act or omission of SEARLE in performing its obligations
under this Agreement or (ii) any claims of patent infringement arising out
of BUYER's sale of Products supplied hereunder which bear the message
referred to in Schedule 14.9 of the Asset Purchase Agreement.
8.3 Notice; Defense. In the event of any claim, action or proceeding for
----------------
which a party is entitled to indemnity hereunder, the party seeking
indemnity ("Claimant") shall promptly notify the other party
("Indemnitor") of such matter in writing. Indemnitor shall promptly but
in no event later than thirty (30) days from date of notice assume
responsibility for and shall have full control of the defense of such
matter and Claimant shall fully cooperate in Indemnitor's handling and
defense thereof. Failure to assume the defense within the aforementioned
time period, shall constitute a waiver of the Indemnitor's rights to
assume the defense and the Claimant shall have the full right to conduct
the defense, settle or otherwise dispose of the claim at the Indemnitor's
expense. The Indemnitor shall have the right to settle or compromise
claims against the Claimant involving the payment of money only in
exchange for an unconditional release of Claimant. All other dispositions
of claims must be approved by Claimant.
8.4 Limitation. Notwithstanding any provision of this Agreement (except for
-----------
Sections 3.6(b) and (c))which might otherwise be to the contrary neither
party shall be liable to the other for lost profits or other consequential
damages of any kind.
ARTICLE 9 -- CONFIDENTIALITY
- ----------------------------
During the term of this Agreement and for a period of three (3) years thereafter
except as otherwise provided in the Asset Purchase Agreement, no party shall,
without the specific written consent of the other party, disclose to any third
party (except to governmental health or regulatory authorities to obtain and
maintain the registration of the Products or other disclosures required by law)
or use for its own purposes any confidential information which is received from
<PAGE>
the other party or its agent(s) pursuant to this Agreement concerning the
Products or the other party's business unless such information:
(a) was or becomes public through no fault of the receiving party, or
(b) was obtained from a third party legally entitled to use and disclose
the same, or
(c) was known to the party prior to entering into this Agreement.
For this purpose, Assets shall be deemed BUYER'S property in the Territory and
not subject to any obligation of confidentiality by BUYER with respect to the
Territory.
ARTICLE 10 -- TERM AND TERMINATION
- ----------------------------------
10.1 Term. The term of this Agreement shall be, unless terminated earlier as
-----
provided herein, for a period of three (3) years commencing on the
Effective Date (the "Initial Term"). This Agreement may be extended upon
the mutual agreement of the parties. BUYER shall notify SEARLE in writing
of its desire to extend the term of this Agreement at least nine (9)
months prior to the expiration of the Initial Term.
10.2 Termination. Either party shall have the right to terminate this
------------
Agreement, immediately upon written notice to the other, during the
Initial Term and any extension thereof:
(a) if the other party is dissolved or liquidated, files or has filed
against it a petition under any bankruptcy or insolvency law, makes
an assignment for the benefit of its creditors or has a receiver
appointed for all or substantially all of its property and is not
withdrawn within thirty (30) days of appointment;
(b) if the other party shall commit any material breach (whether
remediable or not) of its obligations under this Agreement and, if
remediable, shall fail to remedy the breach within (90) days after
receipt of written notice from the non-breaching party describing
such breach;
(c) as to any Product, upon BUYER's or its third party manufacturer's
manufacture of readily saleable quantities of such Product under
BUYER's ANDAs or BUYER's receipt of FDA approval to manufacture any
Product at a BUYER designated facility; provided, however, unless
otherwise agreed by the parties in writing, SEARLE shall fill, and
BUYER shall purchase, the quantities of Products contained in any
firm purchase orders outstanding as of the date of such notice of
termination.
<PAGE>
10.3 Without Prejudice. Termination of this Agreement, due to the fault of
------------------
either party, shall be without prejudice to any other rights or remedies
then or thereafter available to either party under this Agreement or
otherwise.
10.4 Products and Materials. Promptly after expiration or termination, SEARLE
-----------------------
will complete work on all in-process Products. BUYER will pay SEARLE the
price determined pursuant to Section 2.2 for Products Processed or
Packaged by SEARLE. However, in no event shall the quantity of Products
to be purchased by BUYER under this provision exceed BUYER's purchases for
the preceding six (6) month period.
ARTICLE 11 -- GOVERNING LAW
- ---------------------------
This Agreement shall be governed by and interpreted and enforced in accordance
with the laws of the State of Illinois of the United States of America,
regardless of the choice of law principles of Illinois or any other
jurisdiction.
ARTICLE 12 -- MISCELLANEOUS
- ---------------------------
12.1 Changes to Products Definition.
-------------------------------
(a) BUYER shall have the right from time to time, and upon written notice
to SEARLE, to revise Schedule 1.8 by removing pharmaceutical products
listed thereon.
(b) In connection with the Technology Transfer activities described in
the Asset Purchase Agreement, SEARLE shall provide to BUYER
reasonable assistance to locate a supplier of raw materials for the
manufacture of the Products, such assistance is intended to take the
form of activities such as identifying potential suppliers and
facilitating introductions with such suppliers. Nothing contained in
this subsection (c) shall be construed as imposing on SEARLE any
obligation to obtain or secure a supplier on behalf of BUYER.
12.2 Costs. Each party shall bear its own costs and expenses incurred in
------
negotiating this Agreement.
12.3 Notices. Any notice required or permitted to be given hereunder shall be
-------
deemed sufficient if sent by facsimile letter or overnight courier, or
delivered by hand to Seller or Buyer at the respective addresses and
facsimile numbers set forth below or at such
<PAGE>
other address and facsimile number as either party hereto may designate.
If sent by facsimile letter, notice shall be deemed given when the
transmission is completed if the sender has a confirmed transmission
report. If a confirmed transmission report does not exist, then the notice
will be deemed given when the notice is actually received by the person to
whom it is sent. If delivered by overnight courier, notice shall be deemed
given when it has been signed for. If delivered by hand, notice shall be
deemed given when received.
if to Seller, to:
G.D. Searle & Co.
5200 Old Orchard Road
Skokie, Illinois 60077 USA
Attention: Richard Beaver
Director, US Materials Management
Fax number: (847) 581-4038
with a copy to: Assistant General Counsel, Commercial
Fax number: (847) 581-4045
if to Buyer, to:
Watson Laboratories, Inc.
P.O. Box 1900
311 Bonnie Circle
Corona, California 91718-1900
Attention: Dr. Allen Chao
Fax number: (909) 270-1429
with a copy to: Legal Department
Fax Number: (909) 279-8094
No notice by telecopy shall be valid unless confirmed by registered,
airmail letter dispatched within twenty-four hours after dispatch of the
telecopy. Notices shall be deemed to be served as of the earlier of (i)
receipt or (ii) twenty-four hours (in the case of a telecopy) after
dispatch. Any party may, from time to time, notify the other of a
substitute address or telecopy number for notices in the manner set forth
herein.
12.4 Survival. The provisions of Articles 8, 9 and 11 and Sections 2.2(e),
--------
2.4, 2.5, 2.6, 10.3
<PAGE>
and 12.4 shall survive the expiration or other termination of this
Agreement.
12.5 Entire Agreement. This Agreement, together with any Schedules hereto and
----------------
the Asset Purchase Agreement, constitutes the entire agreement between the
parties concerning the subject matter hereof; it may not be modified or
amended except in writing signed by all parties. All agreements or
arrangements (if any) among the parties executed prior to the date hereof
(except for the Asset Purchase Agreement), whether written or oral,
relating to the subject matter hereof are hereby canceled and superseded.
12.6 Headings. Headings are inserted for convenience and shall not by
--------
themselves determine the interpretation of this Agreement.
12.7 Counterparts. This Agreement may be executed in counterparts, each of
------------
which shall be deemed an original, but together constituting one
agreement.
12.8 Assignment. Except as otherwise provided in this Section, neither party
----------
may assign or delegate any right or obligation hereunder without the prior
written consent of the other party, which consent shall not be
unreasonably withheld, and any attempted assignment or delegation in
violation hereof shall be void. BUYER and SEARLE may each assign all of
its rights and obligations hereunder to an Affiliate on notice to and
without the necessity of securing the other party's consent, subject to
and for so long as such assignee remains an Affiliate of the assignor. In
addition, SEARLE may assign all of its rights and obligations hereunder to
a purchaser or successor of all or substantially all of the assets or
business of SEARLE.
12.9 Waiver of Default. No waiver of any default hereunder by any party or any
-----------------
failure to enforce any rights hereunder shall be deemed to constitute a
waiver of any subsequent default with respect to the same or any other
provision hereof. No waiver shall be effective unless made in writing
with specific reference to the relevant provision(s) of this Agreement and
signed by a duly authorized representative of the party granting the
waiver.
12.10 Not for Benefit of Creditors. The provisions of this Agreement are
----------------------------
intended only for the regulation of relations between the parties. Except
as expressly provided in Article 8 (and then subject to the limitations
stated in such Article), this Agreement is not intended for the benefit of
any person, firm or entity not a party hereto and no rights are granted to
such third parties hereunder.
<PAGE>
12.11 Force Majeure. If any party is prevented from performing any obligation
-------------
hereunder by reason of fire, explosion, strike, labor dispute, casualty,
accident, lack or failure of transportation facilities, flood, war, civil
commotion, acts of God, any law, order or decree of any government or
subdivision thereof or any other cause beyond the reasonable control of
such party, then such party shall be excused from performance hereunder to
the extent and for the duration of such prevention, provided it first
notifies the other party in writing of such prevention. The foregoing
shall not apply to any prevention due to any governmental regulatory
action resulting directly from the fault of SEARLE or a third party
manufacturer designated by SEARLE under Section 2.1(c).
12.12 Publicity. Neither SEARLE nor BUYER, nor any Affiliate thereof, will
---------
issue or cause publication of any press release or other announcement or
public communication with respect to this Agreement or the transactions
contemplated hereby without the prior written consent of the other party,
which consent will not be unreasonably withheld or delayed.
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
as of the date first above written.
WATSON LABORATORIES, INC. G.D. SEARLE & CO.
BY /s/ ROBERT FUNSTEN BY /s/ KEVIN K. MC CULLOCH
------------------------------- -------------------------------
Title Secretary Title Authorized Representative
---------------------------- ----------------------------
<PAGE>
EXHIBIT 99.1
NEWS RELEASE
CONTACTS: Watson Pharmaceuticals, Inc.
Sara Swee
Director, Corporate Communications
(909) 270-1400
Morgen-Walke Associates, Inc.
Carolyn Bass, Jim Byers
(415) 296-7383
FOR IMMEDIATE RELEASE
- ---------------------
WATSON PHARMACEUTICALS COMPLETES ACQUISITION OF
THREE ORAL CONTRACEPTIVE PRODUCTS FROM G.D. SEARLE & CO.
CORONA, CA -- November 18, 1998 -- Watson Pharmaceuticals, Inc. (NYSE: WPI)
announced today that Watson's wholly-owned subsidiary, Watson Laboratories,
Inc., has completed its previously disclosed acquisition from G.D. Searle & Co.
("Searle"), a subsidiary of Monsanto Company (NYSE: MTC), of the U.S. rights to
three oral contraceptive products, Tri-Norinyl(R), Norinyl(R) and Brevicon(R),
for $120 million cash. Watson Laboratories, Inc. and G.D. Searle & Co. have also
entered into a supply agreement under which Watson will have the right to
purchase these products from Searle for three years; the first two years in
finished package form and the third year in bulk tablet form.
This press release may contain certain statements of a forward-looking
nature relating to future events or future business performance. Any such
statements that refer to Watson's estimated or anticipated future results,
product performance or other non-historical facts are forward-looking and
reflect Watson's current perspective of existing trends and information. These
statements involve risks and uncertainties that cannot be predicted or
quantified and, consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such risks and
uncertainties include, among others, the success of Watson's product development
activities and the timeliness with which regulatory authorizations and product
roll-out may be achieved,
<PAGE>
market acceptance of Watson's products and the impact of competitive products
and pricing, the availability on commercially reasonable terms of raw materials
and other third party sourced products, dependence on sole source suppliers,
successful compliance with extensive, costly, complex and evolving governmental
regulations and restrictions, the ability to timely and cost effectively
integrate acquisitions, exposure to product liability and other lawsuits and
contingencies, the successful and timely implementation of Watson's Year 2000
Compliance Program, and other risks and uncertainties detailed in Watson's
Securities and Exchange Commission filings.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in
the development, manufacture and sale of proprietary and off-patent
pharmaceutical products. Watson pursues a strategy of generating revenue through
established proprietary and off-patent businesses, capitalizing on its proven
ability to support the development of these drugs in the therapeutic areas of
primary care, women's health, dermatology and neurology/psychiatry.
This and past press releases of Watson Pharmaceuticals, Inc. are available
at Watson's web site at www.watsonpharm.com. In addition, press releases are
-------------------
available through PR Newswire's Company On-Call fax service at (800) 758-5804,
extension 112856, and at www.prnewswire.com.
------------------
# # #
